Environmental Science Advances



View Article Online

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Open Access Article. Published on 12 Diteli 2023. Downloaded on 08/09/2024 3:25:53 AM

CRITICAL REVIEW

Check for updates

Cite this: Environ. Sci.: Adv., 2023, 2, 1488

Promising approaches and kinetic prospects of the microbial degradation of pharmaceutical contaminants

S. Karishma,^a P. R. Yaashikaa,^a P. Senthil Kumar, ⁽⁾*^b R. Kamalesh,^a A. Saravanan^a and Gayathri Rangasamy^{cd}

Pharmaceutical pollutants are released into the environment due to their direct outflow from waste disposal, animal discharge, and drug manufacturing. The long-term health effects on humans and animals due to their biological activity are the negative impacts of pharmaceutical pollutants. Microbial degradation is an effective remediation strategy for removing harmful contaminants from contaminated zones by breaking down foreign substances into smaller useable materials. The novel aspect of the review deals with the advancements and kinetic prospects of the microbial degradation of pharmaceutical pollutants. This review illustrates the classifications, toxic effects on health, occurrences and sources of pharmaceutical pollutants. The interaction mechanism between microbes and pollutants and the molecular mechanism under aerobic and anaerobic conditions are clearly demonstrated in this review. This review discusses in depth the advancements in the field of microbial degradation, such as the utilization of genetically engineered microbes and enzyme immobilization techniques for enhancing the degradation of pollutants. The purpose of this review is to describe the microbial degradation kinetics in order to efficiently supervise the pharmaceutical-contaminated sites. Recent advancements and future prospects for the effective removal of pharmaceutical contaminants are also discussed in depth.

Received 14th July 2023 Accepted 25th September 2023

DOI: 10.1039/d3va00194f

rsc.li/esadvances

Environmental significance

Environmental significance statement for the paper "Promising approaches and kinetic prospects of the microbial degradation of pharmaceutical contaminants." 1. What is the problem/situation? The release of pharmaceutical pollutants has increased worldwide through improper disposal of medicines, drugs and other used compounds from drug manufacturing units. This hinders the biological activity of many living organisms and has a long-term effect on the ecosystem. 2. Why is it important to address/understand this? The remediation of pharmaceutical contaminants is essential for mitigating the negative effects caused by the compounds in the ecological system. Microbial degradation is considered to be one of the effective remediation strategies due to its lack of toxic byproduct release during the process. Micro-organisms have the ability to degrade complex pharmaceutical compounds into simpler substances in the presence of enzymes. Hence, a clear understanding of the mechanisms and advancements in microbe-based degradation of pharmaceutical pollutants is essential for effectively addressing the pollution problems. 3. What is the key finding and what are the implications of this in relation to 1 and 2 above. The molecular mechanism in the microbial degradation of pharmaceutical pollutants is one of the key findings in this review. The interaction of micro-organisms with pollutants adds on for the better understanding of the degradation process. The factors that need to be optimized during the microbial degradation process have been discussed in detail, of which the type of microbial inoculum, pH, and temperature are crucial for better degradation. Advances such as genetic engineering and immobilization enable the complete degradation of pharmaceutical compounds and also inhibit the release of toxic compounds.

1. Introduction

Humans have created a plethora of synthetic compounds for use in a variety of sectors. Some new pollutants have

a significant impact on the ecology, as they are not effectively monitored prior to disposal. Pharmaceuticals play a critical role in improving the quality and expectancy of life of people across the globe. Several medications are used each year to treat infections, illnesses, and other health issues.1 Antibiotic consumption is remarkably high in developing countries, such as India, Russia, and South Africa. Following treatment processes, these residual pharmaceutical substances are released into the environment, causing major medical risks. Pharmaceutical chemicals are classified as emerging pollutants due to their continued use, uncertain environmental and health impacts, and resistance to complete degradation.

^aDepartment of Biotechnology, Saveetha School of Engineering, SIMATS, Chennai 602105, India

^bCentre for Pollution Control and Environmental Engineering, Pondicherry University, Kalapet, Puducherry 605014, India. E-mail: senthilchem8582@gmail.com; senthilkumarp@pondiuni.ac.in

^cSchool of Engineering, Lebanese American University, Byblos, Lebanon

^dUniversity Centre for Research and Development & Department of Civil Engineering, Chandigarh University, Gharuan, Mohali, Punjab 140413, India

Critical Review

Pharmaceuticals have been found in surface and ground water at concentrations of parts per trillion and billion.² Most medications are partially metabolised by organisms into inactive forms. Approximately 75% of antibiotics are excreted as active metabolites. Nonsteroidal medications are highly water-soluble chemicals that are partially destroyed and have a negative influence on the environment.^{3,4}

Extensive pharmaceutical distribution is a major concern as it poses serious threats worldwide.⁵ Active chemicals, such as hormone receptors are detrimental to marine organisms in the setting of an aquatic system. To control the hazardous pharmaceutical pollution, certain discharge regulations are required under standard settings. High aqueous-based discharges must be closely monitored and recognised in order to hypothesise on the best ways for removing and degrading pharmaceutical compounds from water sources. Apart from these, pharmaceutical contaminants also come in the form of agricultural runoff, which might include pesticides.⁶⁻⁸

Pharmaceutical pollutants, including high COD concentrations, vary depending on industrial discharge. Nitrogen usage in antibiotic manufacturing increases nitrogen concentrations, but no legally controlled legislation or system is in place to mitigate these pollutants.9,10 In general, chlorination is the most commonly used procedure for purifying drinking water. Overall, physicochemical methods are used first, followed by secondary treatment processes involving biological reactions. Adsorption is favoured in fundamental physicochemical processes for the elimination of some medicinal substances, and organic and inorganic pollutants. Advanced oxidation and precipitation procedures can be used to eliminate bio-organic substances. However, certain residual medications such as ibuprofen, iopromide, and sulfamethoxazole are still present in the effluent and must be treated using subsequent biological processes.11,12

Microbial species are important xenobiotic degraders that aid in the maintenance of correct ecological balance. Microbial degradation is a highly effective approach for removing dangerous pharmaceutical pollutants from the environment (Ramesh et al., 2023). The pharmaceutical breakdown rates are primarily determined by factors such as the composition of the microbial culture, medicines, pH, and temperature. Microorganisms play an important role in the environment via several biodegradation pathways involving enzymes, metabolites, and co-metabolites.13-15 Furthermore, the use of microbial breakdown mechanisms can greatly lower the toxicity of active medicinal compounds. In nature, the interaction between microorganisms and drugs is non-inhibitory. Basic molecular biology and engineering principles are used in preliminary procedures that provide an imperfect solution to metabolic mechanisms.16

Recent innovations in genetic engineering domains, such as recombinant techniques, allow for a shift in practical applications. Microbial systems are built in such a way that enzyme switching to mineralization of medicinal substances is possible. Synthetic biology and system biology, two topics related to systemic biology, aid in reducing the obstacles and drawbacks connected with earlier conventional microbial degradation processes.17,18 The principles of sustainable metabolic and synthetic engineering help maximise the sustainability of pharmaceutical degradation. Current studies have resulted in the successful rebuilding of metabolic pathways. Another recent breakthrough is the immobilisation of microbial cells in an appropriate carrier material. The immobilisation of biodegrading organisms in biofilm systems has advantages in terms of ease of use, operation, and economics. Enzymes or bacteria/fungi with degrading capacity can be immobilised in an intact system with an inert carrier material. As a result, microbial immobilisation contributes to being a prospective candidate in recent improvements. Different kinetic models can be used to predict the mechanism of biodegradation.¹⁹⁻²¹ The literature previously has not focused on the recent advancements with the kinetic aspects of the microbial mediated remediation of pharmaceutical pollutants. This review article specifically focusses on the kinetic prospects and advances like metabolic or genetic engineering with immobilization for the microbial degradation of pharmaceuticals.

The primary concern of the review has been on the mechanisms and advances in the microbial degradation of pharmaceuticals. The paper provides a comprehensive summary of several pharmaceutical pollutant groups, their sources, and the accompanying health impacts. The interaction of microorganisms and pharmaceutical pollutants, as well as their chemical mechanism, has been described. The review discusses the recent advances in the microbial realm, such as metabolic engineering and cell immobilisation. The description of the degradation kinetic analysis aids in the determination of the mechanisms involved in pharmaceutical contaminant elimination.

2. Pharmaceutical pollutants

2.1 Classifications

Antivirals, anti-inflammatories, anti-convulsants, antibiotics, and analgesics are the major prevalent pharmaceutical pollutants. Table 1 lists the classification and characteristics of pharmaceutical pollutants.²²⁻⁴⁵ Antiviral medications are used to treat viral infections such as influenza, hepatitis, polio, measles, and small pox by inhibiting the pathogen growth. Antiviral medicines are more active in nature during viral propagation. Antiviral medications impede viral attachment entry into the cell, nucleic acid synthesis with protein synthesis, and eventually packaging and vital release into the environment. Amantadine, gancyclovir, zidovudine, nevirapine, and emtricitabine are examples of common antiviral medicines.46,47 Antiviral medications are commonly found in aquatic systems such as wastewater, effluents, surface water, and ground water. Antibiotics are additional developing pharmaceutical contaminants that are widely used in the veterinary and health industries. Antibiotics are medication classes used to treat bacterial illnesses in humans and animals by inhibiting growth or metabolism and killing the bacterium. Antibiotics are primarily produced by microorganisms to accomplish a variety of activities. They can function as predators with an attacking mechanism or as a chemical weapon with a defensive mechanism.48,49

S. no.	Classification of pharmaceutical	Pharmaceutical compounds	Chemical formula	CAS ID	Molar mass $(g \text{ mol}^{-1})$	Boiling point (°C)	Melting point (°C)	p <i>K</i> a	References
1.	Antivirals	Acyclovir	$C_8H_{11}N_5O_3$	59277-89-3	225.21	595	256.6	2.52	22
		Adefovir	$C_8H_{12}N_5O_4P$	142340-99-6	273.186	632.5	102	1.35	23
		Amantadine	$C_{10}H_{17}N$	665-66-7	151.25	360	180	10.1	24
2.	Non-steroidal	Aspirin	$C_9H_8O_4$	50-78-2	180.158	140	136	2.97	25
	anti-	Ibuprofen	$C_{13}H_{18}O_2$	15687-27-1	206.29	157	75-77	5.2	26
	inflammatory	Naproxen	C14H13NaO3	22204-53-1	230.26	403.9	153	4.2	27
	drug	Diclofenac	$C_{14}H_{11}Cl_2NO_2$	15307-86-5	296.148	412	302-310	4	28
		Celecoxib	$C_{17}H_{14}F_3N_3O_2S$	169590-42-5	381.373	529	161-164	11.1	29
		Etoricoxib	$C_{18}H_{15}ClN_2O_2S$	202409-33-4	358.842	510	135-137	4.5	30
3.	Anti-convulsant	Pregabalin	$C_8H_{17}NO_2$	148553-50-8	159.23	85	196	4.2	31
		Phenytoin	$C_{15}H_{12}N_2O_2$	57-41-0	252.268	464	298	2.3,	32
								8.3	
		Ethosuximide	$C_7H_{11}NO_2$	77-67-8	141.168	265.3	64.5	8.2	33
		Topiramate	$C_{12}H_{21}NO_8S$	97240-79-4	339.363	438.7	125	1.4,	34
								4.3	
1.	Antibiotics	Erythromycin	C37H67NO13	114-07-8	733.93	818.4	135-140	8.88	35
		Sulfamethoxazole	$C_{10}H_{11}N_3O_3S$	723-46-6	253.279	482.1	169	3.92	36
		Azithromycin	C38H72N2O12	83905-01-5	785	822.1	129-135	8.5	37
		Trimethoprim	$C_{14}H_{18}N_4O_3$	738-70-5	290.32	405.2	199-203	7.1	38
		Levofloxacin	C18H20FN3O4	100986-85-4	361.368	571.5	213-218	5.35	39
		Cephalexin	$C_{16}H_{17}N_3O_4S$	15686-71-2	347.39	727.4	326.8	3.45	40
5.	Analgesics	Codeine	C ₁₈ H ₂₁ NO ₃	76-57-3	299.364	462	154	8.2	41
	0	Fentanyl	$C_{22}H_{28}N_2O$	437-38-7	336.471	466	87.5	8.05	42
		Hydrocodone	$C_{18}H_{21}NO_3$	125-29-1	299.368	65	118-128	8.9	43
		Meperidine	$C_{15}H_{21}NO_2$	57-42-1	247.33	328.9	186-189	8.63	44
		Methadone	$C_{21}H_{27}NO$	76-99-3	309.445	423.7	235.54	9.2	45

The first antibiotics are penicillin compounds produced from organic components *via* chemical synthesis or modification. Antibiotics are further categorised as bacteriostatic or bactericidal based on their method of action.⁵⁰

Non-steroidal anti-inflammatory medications are a large class of therapeutics with a vast functional variety that is used to alleviate pain and inflammation. Aromatic groups with acidic functional moieties are common in anti-inflammatory medicines.⁵¹ A broad classification based on chemical forms includes oxicams, salicylates, acid, indole derivatives, and anthranilates. The majority of anti-inflammatory medications are attached to plasma proteins, which improves the bioavailability by allowing them to cross the organ barrier. Anti-inflammatory medications have notable effects such as tumour cell induction, DNA damage protection, and neogenesis inhibition.⁵²

Anticonvulsants, frequently referred to as antiseizure or antiepileptic medications, have the ability to regulate convulsions caused by electrical activity in the brain.⁵³ Antiepileptic medications give the necessary seizure relief. Phenytoin, benzodiazepine, primidone, and phenobarbital are examples of common anticonvulsants. More than 30% of persons are resistant to anticonvulsant medications that result in significant side effects during seizure management. Hormones are the most common drug classes in the pharmaceutical industry. Underactive hormone secretion will be treated with synthetic hormone replacement therapy.^{54,55} Other pharmaceutical pollutants found in the environment include antidepressants and antipyretics. Certain classes of pesticides also come under such disinfectants, and wormicides also come under pharmaceutical class of contaminants. Fig. 1 represents the classification and health effects of pharmaceutical pollutants.

2.2 Health effects

Pharmaceuticals react biologically differently to various particular and non-specific species. Pharmaceuticals with low concentrations can be found in the environment for extended periods of time. The bioavailability of pharmaceuticals and their associated health ailments are tabulated in Table 2.56-67 The toxic effects on aquatic organisms exposed to pharmaceutical contaminants alter their lifetime. Analgesic exposure in the environment causes kidney diseases and morphological abnormalities in the gills. Pollutants at 1000–3000 g L^{-1} concentrations might cause acute renal failures with changes in foetal anomalies.^{68,69} Fish are noteworthy organisms harmed by excessive pharmacological concentrations. Pharmaceutical pollutants cause structural disturbance with changes in gene expression and the reproductive system, which are the major governing mechanisms. Aside from fish, several algae are vulnerable to the negative effects of medications.⁷⁰ In plants, fatty acid production is a critical step in the photosynthetic process. Chronic toxicity in the photosynthetic machinery of both algae and plants has been found, impairing chloroplast function. Because of their active nature, hormones, even at low doses, can pose substantial health risks. This causes considerable endocrine disturbance in fish, resulting in estrogenic




Table 2 Bioavailability of the pharmaceutical and their associated health ailments

S. no.	Pharmaceuticals	ChEMBL Id	Bioavailability	Administrative route	Dosage	Health ailments	References
1.	Acetaminophen	112	70-90%	Oral, rectal, and intravenous	$150 \mathrm{~mg~kg^{-1}}$	Abdominal pain, diarrhea, irritability, and vomiting	56
2.	Cimetidine	30	60%	Oral, and intravenous	400 mg/per day	Reversible impotence or gynecomastia	57
3.	Digoxigenin	1153	70-80%	Oral	0.25 mg/per day	Ventricular arrhythmias, hypotension, symptomatic bradycardia	58
4.	Carbamazepine	108	75-85%	Oral	200 mg/per day	Coma, imbalance, dizziness, and drowsiness	59
5.	Warfarin	1464	100%	Oral	7.5 mg/per day	Joint pain, bleeding, vision change, significant hemorrhage	60
6.	Albuterol	714	21-27%	Inhalation route	4 mg/3–4 times a day	Cough, throat irritation, vomiting	61
7.	Ciprofloxacin	8	70%	Oral, and intravenous	1000 mg/per day	Tendinitis, tendon rupture	62
8.	Codeine	485	60%	Oral	240 mg/per day	Acute pancreatitis, liver damage	63
9.	Dehydro nifedipine	193	45-68%	Oral, and intravenous	120 mg/per day	Flushing, peripheral edema, dizziness, and headache	64
10.	Diltiazem	23	40%	Oral	240 mg/per day	Headache, allergic reactions	65
11.	Doxycycline	1433	73–95%	Oral	200 mg/per day	Bloating, blistering, decreased appetite	66
12.	Metformin	1431	40-60%	Oral	500 mg/per day	Lactic acidosis	67

effects. Cyanobacteria and algae have a higher histopathological index and are more antibiotic resistant.71,72 When exposed to tetracycline chemicals, oxidative DNA damage with metal complex formation has been reported. Atorvastatin exposure had a significant impact on lipid regulators with beta blockers in both target and non-target organisms. Because of their high sorption nature and affinity in sediments, enzymes involved in the beta receptor activity represent a risk to aquatic animals. Neurotoxicity is the most common health problem associated with psychiatric medicines in effluents or municipal wastewater systems. Anticancer drugs at concentrations ranging from 0.1 to 0.3 mg L^{-1} have an effect on optical acuity and mutagenicity. Endocrine disruptors induce reproductive and digestive system disruption. Males experience hypogonadism as a result of ibuprofen contraindications.73-75 These pesticide compounds may enter into water systems through surface run-off or leaching. Indirect toxic effects on the fishes with impairment in the metabolic system of primary producers are few ailments related to aquatic species. Hormonal imbalance, neurological dysfunction, blood disorders, and immune impairment are the known effects of pesticides in the health system.⁷⁶ As a result, pharmaceutical exposure leads to expanding health and environmental problems.

2.3 Sources and occurrence

Without suitable treatment techniques, pharmaceutical chemicals are widely discharged into the environment. Pharmaceuticals are also used in different agricultural elements for disease prevention and treatment. Pharmaceutical use has increased in recent years due to its physicochemical and biochemical action modes. Certain molecules are metabolised during drug delivery, while others stay intact prior to elimination. Because of their low volatile and highly polar character, these metabolites remain stern and are not excreted into systems or disposed of in waste effluents. Pharmaceutical contaminants are unlikely to enter the environment via industrial disposal channels.77,78 Pharmaceutical chemicals are classified into two types: point sources and non-point sources. Pharmaceuticals are most typically introduced into the environment by sewage sludge dumping, groundwater leaching, and surface run off. Medical chemicals have been found in municipal and hospital effluent sewage. Hospital sludge has a higher concentration than that of municipal sludge. Expired medications are dumped in home sewage. Pharmaceuticals are also present in landfills; however, they are less concentrated due to their sorption or breakdown capabilities. Primary and secondary point sources of pharmaceutical pollution are landfills and wastewater. Sewage treatment plants contain considerable amounts of medicines that remain unmetabolized for extended periods of time.79 Duan et al. (2021) investigated the occurrence and source analysis of pharmaceutically active components in China City's aquatic systems. Diclofenac acid, carbamazepine, and caffeine are the most commonly detected substances. Besides, high lincomycin concentrations (81.1 ng L^{-1}) are frequent in the antibiotic class. Other medications detected in average concentrations (16 to 21 ng L^{-1}) include sulfamethoxazole, roxithromycin, and

erythromycin.^{80,81} The investigation also revealed that the target compounds were detected in low amounts and that non-antibiotics were more frequent in the ecosystems.


3. Microbial degradation

3.1 Molecular mechanism and interaction of microbes with pharmaceutical pollutants

Many organic and inorganic compounds are degraded significantly by microorganisms. Microbial systems play a significant role in ecosystem functioning since they are a key community. When medicines enter the ecosystem, many processes such as sorption, hydrolysis, and biodegradation occur, which prevents ecotoxicity in environmental systems. Microbial degradation is the best strategy in the environmental aspect for effective harmful pollutant removal.82 Natural creatures in water and soil are significant players in environmental process management. They also control the release of drugs into the environment. Microbial species participate in the degradation and purification processes via metabolic and co-metabolic pathways. The two primary biodegradation pathways are bio-oxidation and hydrolysis. The enzymes involved in metabolic and cometabolic pathways aid in pharmacological transformation.83 Fig. 2 depicts the interaction mechanism between microbes and pharmaceutical pollutants.

Microbial biodegradation can be categorised into three stages: bioattenuation, biostimulation, and bioaugmentation.84 Bioattenuation is the inclusiveness of organisms to improve metabolic activity and pharmaceutical breakdown. Limited nutrients are added to enable the microbial species to degrade harmful contaminants. Supplementary organisms are added to microflora for specific impurities during the bioaugmentation process. By metabolising pollutants, microorganisms use pharmaceutical contaminants as their sole source of growth. Pharmaceutical contaminants can be completely mineralized during the biodegradation process.85,86 The biodegradation of pharmaceuticals has the benefit of both aerobic and anaerobic mineralization. In terms of bacteria-based biodegradation, a mixed bacterial consortium is favoured since it has a variety of enzymes capable of degrading the chemicals. Several investigations have been conducted on the breakdown of particular medicinal components by specific bacterial species. In one investigation, the Achromobacter sp. destroyed sulfamethoxazole. Pharmaceutical wastewater sediments were used to isolate the bacterial species. The bacterial culture must first adjust to its new habitat before beginning the degradation process. For strain growth, sulfamethoxazole was used as an electron donor and carbon source.87,88

Diclofenac was also subjected to biodegradation by *Labrys portucalensis* sp. in another investigation. This mechanism was primarily identified by the detection of metabolites. The reaction begins with hydroxylation reactions, which result in isomer formation. The hydroxylation reaction takes place using mono and dioxygenase enzymes released by *Labrys* sp. as the first step in the microbial degradation process. The enzyme methyl transferase adds a methyl group to 4-hydroxy diclofenac molecules. The decarboxylase enzymes then participate in the



intermediate process. The auto-oxidation of hydroxylated metabolites occurs *via* an alternative pathway, resulting in benzoquinone molecules. Diol dehydrogenases fission rings, resulting in Kreb's cycle intermediates and simpler metabolite molecules.⁸⁹ After 24 hours of treatment, diclofenac had a comparable response to *Chlamydomonas reinhardtii*. The concentration of metabolites was also observed to rise with the cell biomass.⁹⁰

Other microbial species that participate in the pharmaceutical breakdown process include fungi. Pharmaceutical substances are broken down by extracellular multi-enzyme complexes. Olicon-Hernandez et al. (2019)91 investigated ascomycete fungus species' degradation of diclofenac compounds. Penicillium oxalicum was isolated from hydrocarbon-polluted materials and employed in flask and bench scale reactors for biodegradation. For free Penicillium sp., the clearance rate was greater than 99%. During biodegradation mechanisms, hydroxylated metabolites linked with phase 1 and phase 2 detoxification pathways are formed concurrently. The inclusion of transferase enzyme in the process mechanism facilitates the formation of high conjugate metabolites - diclofenac acyl glucuronide.91 Trametes pubescens was used to breakdown clofibric acid, another pharmaceutically active molecule. Trametes sp. consumes clofibric acid as a substrate, which has both antagonistic and synergistic effects. Trametes, a white rot fungal, undergoes oxidation followed by the production of metabolite intermediates. The fungal-based microbial degradation reached around 30% degradation.92 In the microbial degradation of pesticides, pesticides are utilized as microbial nutrient sources, which are consequently degraded into small compounds. Mechanisms involved in the degradable pathways are hydrolysis, reduction, decarboxylation, condensation, dehydrogenation, and oxidation. Initially, adsorption of pesticides occurs on the cell membrane surface. Second, mineralization of the organic compounds to simple inorganic

compounds takes place under the influence of enzymatic action. In addition, microbial pesticide degradation includes co-metabolism as a primary mechanism.^{93,94} Chen *et al.*⁹³ explored the metabolic pathway for the chloracetamide degradation by microbial species. Different biological and physiological reactions such as hydroxylation, dechlorination, and dealkylation have been observed in the microbial degradation of chloracetamide pesticides.⁹³ Different microbial remediation studies on the removal efficiency of pharmaceutical pollutants are listed in Table 3.⁹⁵⁻¹¹⁹

3.2 Influencing factors

Certain biotic and abiotic variables generally influence the biodegradation process. In terms of microbial degradation, the factors associated with microbial growth and processing are growth source, temperature, pH, and nutrient source. Besides, pharmaceutical features and microbial culture incubation with medicines have an important influence on the degradation process.¹²⁰

pH is a vital component in the microbe-based degradation process because it influences enzymatic activity, proliferation, adaptability, shape, and certain membrane properties. The acidic and alkaline pH values are intimately related to the ionic form of medicinal substances, which influences the degradation process indirectly.¹²¹ In a study of ibuprofen degradation by *Bacillus thuringiensis*, it was discovered that a pH in the range of 6 to 7 was optimal for maximum ibuprofen degradation. The bacterial enzymes hydroquinone monooxygenase and hydroxyquinol 1,2-dioxygenase are most active at pH levels between 7 and 8, which may have altered the breakdown process. The uncharged form of ibuprofen interacts with the bacterial cell surface releasing enzymes, leading to disintegration.¹²²

Temperature is an essential factor that influences the microbial breakdown process. The chemical reaction doubles

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. (cc) BY-NC

Open Access Article. Published on 12 Diteli 2023. Downloaded on 08/09/2024 3:25:53 AM.

Erythronycin500 mV, 27 °CSEMSulfamethazine35 °C, pH 7.0, and inoculationLCMS, whole genome sequencing sequencing incutationLCMS, whole genome sequencing sequencing incutationSulfamethoazzole35 °C, 180 rpm, 24 hLCMS, whole genome sequencing incutationErythromycin37 °C, 180 rpm, 18 hThiamphenicol37 °C, 130 rpm, 18 hThiamphenicol23 °C, 130 rpmProteomic and metabolonic analysis Uvspec, RT-PCRCefuroxine, and cefpirome mixture23 °C, 130 rpmThiamphenicol23 °C, 130 rpmUV, PCR, HPLC37 °C, 220 rpmDiclorascolin30 °C, 120 rpmDiclorascolin30 °C, 120 rpmUV, PCR, HPLCDiclorascolin30 °C, 120 rpmDiclorascolinSiltidiazine30 °C, 120 rpmDiclorascolinDiclorascolin30 °C, 120 rpmDiclorascolinDiclorascolin30 °C, 120 rpmDiclorascolinDiclorascolin30 °C, 120 rpmDiclorascolinDiclorascolin30 °C, 120 rpmDiclorascolin <th>S. no.</th> <th>Microbes</th> <th>Pharmaceuticals</th> <th>Operating condition</th> <th>Technique used</th> <th>Efficiency</th> <th>Time</th> <th>References</th>	S. no.	Microbes	Pharmaceuticals	Operating condition	Technique used	Efficiency	Time	References
Genometer, and Bacilias ceress H38 Sulfamethasine 50 mV, 27 °C SEM Bacilias ceress H38 Sulfamethasine 35 °C, PH 7.0, and inoculation LCMS, whole genome sequencing proteomic statzer, and Splitg inocasts Sulfamethasine 35 °C, FM 7.0, and inoculation LCMS, whole genome sequencing proteomic statzer, and Splitg inocasts Proteomic statzer, FM 20, and 1% (VN) Whole genome sequencing sequencing proteomic analysis Splitg inocasts Thiamphenicol 37 °C, 130 pm Proteomic analysis Splitg inocasts Celtroxime, consulture statzer, and Splitg inocasts 37 °C, 130 pm Proteomic analysis Bacillas datasti Celtroxime, celtronom astruction for the station of the station station of the station for the station of the station for the station mixture sector induces and datapentin 37 °C, 130 pm Proteomic analysis Richstella sp. Celtroxime, celtronom astruction for the station for	Bacteria							
Bacilias cerese H38 Sulfamethazine 37 °C, H30 T, 70, and inoculation ECMS, whole genome Preudemonas statzeri, and Sulfamethosazole 39 ± 1 °C, 180 Tpm, 24 h HPLC-MS Periadencias statzeri, and Sulfamethosazole 39 ± 1 °C, 180 Tpm, 24 h HPLC-MS Periadencias statzeri, and Sulfamethosazole 37 °C, 180 Tpm, 18 h - - Splitige locatoria Thismphenicol 37 °C, 130 Tpm Proteomic and sequencing - Splitige locatoria Ceftrostine, and 37 °C, 130 Tpm Proteomic and/sis - Bacillas diasti Ceftrostine, and 37 °C, 130 Tpm Proteomic and/sis - Rebsiella sp Tetraspecial 37 °C, 130 Tpm DroteOmic analysis - Rebsiella sp Tetraspecial 37 °C, 130 Tpm DroteOmic analysis DroteOmic analysis Rebsiella sp Tetraspecial So °C, 130 Tpm DroteOmic analysis DroteOmic analysis Refsheld sp Tetraspecial So °C, 130 Tpm DroteOmic analysis DroteOmic analysis Leadina Ceftorasine So °C, 130 Tpm DroteOmic and construc	1.	Geobacter, and Acetoanaerobium	Erythromycin	500 mV, 27 °C	SEM	%66	4 days	95
Pseudomones statzeri, and Deginating purefactions Buildmethoacus 31 ° C, 180 rpm, 18 h H"LC-MS" Providencia purefactions Explinioning incursion 37 ° C, 180 rpm, 18 h - - Springing incursions Explinioning incursion 37 ° C, 130 rpm, 18 h - - Springing incursions Explinioning incursion 37 ° C, 200 rpm UPLC-UV Viole genome sequencing incursion Springing incursion Ceftorosime, and ceftorosime, and ceftorosime, and ceftoroning incursion 37 ° C, 220 rpm Viole genome sequencing incursion Reading explores Ceftorosime, and ceftoroning incursion 37 ° C, 220 rpm Viole genome sequencing incursion Reading explores Ceftorosime, and ceftoroning incursion 37 ° C, 200 rpm UPLC-UV Mittracconsisting incursion Diclorent of the solution 37 ° C, 200 rpm UPLC-QTOF, UPLC-UV Mittracconsistine, and ceftoron mixture Ceftoroning and solution 37 ° C, 200 rpm UPLC-QTOF, UPLC-UV Mittracconsistine, and ceftoron mixture Ceftoroning and solution 30 ° C, 120 rpm Mittra-GS Mittracconsistine, and ceftoron mixture Cephalosporin UPLC-QTOF, UPLC-UV UPLC-GTOF	2.	Bacillus cereus H38	Sulfamethazine	25 °C, pH 7.0, and inoculation amount 5%	LCMS, whole genome sequencing	100%	3 days	96
Defini latasiris Expensioneri prividencia stratti Tytosin 37 °C, 130 pm Mole genome sequencing incontation - Sphingernenus sp. Thiamphenicol 23 °C, 130 pm Woole genome sequencing incontation Mole genome sequencing incontation Readiments Celusine, and celosine mature transferations 37 °C, 220 pm UPLC-CPC, UPLC-UV UV, PCK, HPLC Natrococcus tureus NLSM.1 Dielofenac sodium 30 °C, 120 pm, 72 h ESSM, LC-ESIAS Matrococcus tureus NLSM.1 Dielofenac sodium 38 °C, 100 pm, 72 h ESSM, LC-ESIAS Leades Terasperine 25 °C ± 2 °C, 100 pm UPLC-MS Leades Terasperine 25 °C ± 2 °C, 100 pm UPLC Leades Terasperine 25 °C ± 2 °C, 100 pm UPLC Leades Terasperine 25 °C ± 2 °C, 100 pm UPLC	3.	Pseudomonas stutzeri, and Shewanella putrefaciens	Sulfamethoxazole	$30 \pm 1 ^{\circ}\text{C}$, 180 rpm, 24 h	HPLC-MS	61.79%, and 68.67%	5 days	97
Prividencia strarti Tyloshi 15, h, 40 °C, pH 70, and 1% (vv) Whole-genome sequencing incondition Sphingomentas sp. Thiamphenicol 3° °C, 130 pm Proteomic and incondition Bacillus clausit Ceturoxine, cefonisme, and cetorixine, and cetorixine, and cetorixine, and cetorixine, and cetorixine, and cetorixine, and thereoccus luteus NISM.1 Tot, 220 pm Proteomic and metaboline analysis Klabsiella sp. Tectorixine, cetorixine, and cetorixine, and cetorixine, and cetorixine, and cetorixine, and thereoccus luteus NISM.1 Diclorenas colitim Diclorenas colitim Jacroscoccus luteus NISM.1 Diclorenas colitim 30 °C, 120 pm UV, PCR, HPLC Marcoccus luteus NISM.1 Diclorenas colitim 30 °C, 120 pm UV, PCR, HPLC Itentinia dadia Diclorenas colitim 30 °C, 120 pm UVCAPRE Itentinia badia Conscillin 38 °C, 130 pm, 72 h UVCANS Itentinia actierme RJ12 Nonclitenas colitin 38 °C, 130 pm UVCANS Itentinia badia Tricholemac 38 °C, 130 pm UVCANS UVCANS Pericillium ocalicum Diclorenas colitin 38 °C, 130 pm UVCANS UVCANS Pericillium ocalicum <t< td=""><td>4.</td><td>Delftia lacustris</td><td>Erythromycin</td><td>37 °C, 180 rpm, 18 h</td><td> </td><td>45.18%</td><td>5 days</td><td>98</td></t<>	4.	Delftia lacustris	Erythromycin	37 °C, 180 rpm, 18 h		45.18%	5 days	98
Sphingements sp. Thiamphenicol $25 \circ C_1 50 \text{ pm}$ Proteomic and certistic claustic Proteomic and certistic constructs $37 \circ C_2 20 \text{ pm}$ Proteomic and verspect RT-PCR Bacillus clausti Cefurostine, and certionsine, and certionsine, and certionsine, and certionsine arruptine $37 \circ C_2 20 \text{ pm}$ Verspec, RT-PCR Klabsiella sp. Tetraspeline $35 \circ C_1 20 \text{ pm}$, 72 h UPLC-Q-TOF, UPLC-UV Klabsiella sp. Tetraspeline $35 \circ C_1 20 \text{ pm}$, 72 h UVLC-Q-TOF, UPLC-UV Readomons arruptine $35 \circ C_1 120 \text{ pm}$, 72 h $00 \circ C_1 120 \text{ pm}$ UPLC-Q-TOF, UPLC-UV Readomons arruptine $05 \circ C_1 120 \text{ pm}$, 72 h $00 \circ C_1 120 \text{ pm}$, 72 h UPLC-Q-TOF, UPLC-UV Relabeling sp. Dictorate solium $30 \circ C_1 120 \text{ pm}$, 72 h UPLC-Q-TOF, UPLC-UV Interind acides and Cephalosporiu $35 \circ C_1 120 \text{ pm}$, 72 h UPLC-Q-TOF, UPLC-UV Interind acides and Cephalosporiu $35 \circ C_1 20 \text{ pm}$, 72 h UPLC-Q-TOF, UPLC-UV Interind acides and Cephalosporiu $10 \circ C_1 120 \text{ pm}$, 72 h UPLC-MS Interind acides and Cephalosporiu $10 \circ C_1 10 $	5.	Providencia stuartii	Tylosin	15 h, 40 °C, pH 7.0, and 1% (v/v) inoculation	Whole-genome sequencing	100%	3.5 days	66
Bacillus dausii Cefuroxime, cefoixime, and cefoixime, and cefoixime mixture 3° °C, 220 pm UrLC-Q-TOF, UPLC-UV Rebsiella sp. Tetracycline mixture 2° °C, 5 min, 630 W UPLC-Q-TOF, UPLC-UV Paudomenus aeruginosa Diclostantlin 3° °C, 120 pm, 72 h UPLC-Q-TOF, UPLC-UV Rebsiella sp. Tetracycline 3° °C, 120 pm, 72 h UPLC-Q-TOF, UPLC-UV Micrococas lucas NLSM.1 Diclotenac solium 3° °C, 120 pm, 72 h UPLC-MS Micrococas lucas NLSM.1 Diclotenac solium 3° °C, 120 pm, 72 h UPLC-MS Micrococas lucas NLSM.1 Diclotenac solium 3° °C, 120 pm, 71 h UPLC-MS Imleria badia Cephalosporin Ultrasound at 9 kHz, 20 min UPLC-MS Interia badia Casher Ultrasound at 9 kHz, 20 min UPLC-MS Interia badia Costality FIR MIT Diclotenac 3° °C, 140 pm I taddes Testosterone 3° °C, 140 pm UPLC, UV-Spec I taddes Testosterone 3° °C, 20 rpm UPLC, UV-Spec I taddes Testosterone 3° °C, 20 rpm UPL	.9	Sphingomonas sp.	Thiamphenicol	25 °C, 150 rpm	Proteomic and metabolomic analysis	93.9%	1.5 days	100
Klebsiella sp.Teriacycline $25 \circ C_1 5 \min , 630 W$ UPLC-Q-TOE, UPLC-UVPseudomonas aeruginosaDiclosascillin $30 \circ C_1 20$ UV, PCR, HPLCNatrococcus luters N.SM.1Gabapaentin $30 \circ C_1 120$ pm, 72 hUV, PCR, HPLCRebsiella sp.Diclosascillin $30 \circ C_1 120$ pm, 72 hUV, PCR, HPLCLentinula etodes andCephalosporin $30 \circ C_1 120$ pm, 72 hUPLC/MSLentinula etodesCephalosporinUltrasound at 49 kHz, 20 minUPLC/MSLeptosphaerulina sp.Cascillin $28 \circ C_1 140$ pmUPLC/MSLeptosphaerulina sp.Oxacillin $28 \circ C_1 120$ ppmUPLC/MSLedoes17.2-Ethinylestratiol $25 \circ C \pm 2 \circ C_1 00$ ppmUPLC/MSL edodes17.2-Ethinylestratiol $28 \circ C_1 20$ ppmUPLC/MSL edodes17.7-Ethinylestratiol $28 \circ C_1 120$ ppmUPLC/MSPenicillium contruueOsytetracycline $25 \circ C \pm 2 \circ C_1 00$ ppmUPLC/MSPenicillium contruueOsytetracycline $28 \circ C_1 20$ ppmUPLC/MSPenicillium contruueOsytetracycline $28 \circ C_1 20$ ppmUPLC/MSPenicillium contruueOsytetracycline $28 \circ C_1 20$ ppmPHLC/MSPenicillium contruueO	7.	Bacillus clausii	Cefuroxime, cefotaxime, and cefpirome mixture	37 °C, 220 rpm	Uv-spec, RT-PCR	100%	0.5 day	101
Pseudomorus aeruginosaDiclovacillin $30 \circ C_{1} 20 \text{ rpm}, 72 \text{ h}$ UV, PCR, HPLCMicrococcus luteus N.ISM.1Diclofenac sodium $30 \circ C_{1} 120 \text{ rpm}, 72 \text{ h}$ FE-SSM, LC-ESI-MSMicrococcus luteus N.ISM.1Diclofenac sodium $30 \circ C_{1} 120 \text{ rpm}, 72 \text{ h}$ FE-SSM, LC-ESI-MSLentinula edodes andCephalosporinUltrasound at 49 kHz, 20 minUPLC/MSLeptospharentina sp.Oxacillin $30 \circ C_{1} 120 \text{ rpm}, 72 \text{ h}$ Biotransformation andLeptospharentina sp.Oxacillin $30 \circ C_{1} 20 \circ C_{1} 140 \text{ rpm}, 10 \text{ PLC/MS}$ MTT assayLeadodsTestosterone $25 \circ C \pm 2 \circ C_{1} 100 \text{ rpm}, 10 \text{ PLC/MS}$ MTT assayLeadodsTestosterone $25 \circ C_{1} 20 \circ C_{1} 00 \text{ rpm}, 10 \text{ PLC/MS}$ MTT assayPenicillium oxalicumOxytetracycline $25 \circ C_{1} 120 \text{ rpm}, 10 \text{ PLC/MS}$ Optical and scanningPenicillium oxalicum RU2Trohoderma cprinoridita 17 -bestradiol (E2) $28 \circ C_{1} 120 \text{ rpm}, 10 \text{ PLC/MS}$ PPLC, 0VSpecPenicillium oxalicum RU2So C_{1} PH 5.7Optical and scanningOptical and scanningPenicillium oxalicum RU2Trohoderma cprinoridita 17 -bestradiol (E2) $28 \circ C_{1} 120 \text{ rpm}, 10 \text{ PLC}, 00 \text{ rescopyPanaroordaterSo C_{1} PL 5.7Optical and scanningOptical and scanningPhaneroordaterSo C_{1} 100 \text{ rpm}, 10 \text{ PLC}, 00 \text{ rescopyOptical and scanningPhanerooleaterTrohoderma cprinoridia17-bestradio (E2) PL 5.7Optical and scanningPhanerooleaterSo C_{1} 100 \text{ rpm}, 10 PLC$	8.	Klebsiella sp.	Tetracvcline	25 °C. 5 min. 630 W	UPLC-O-TOF. UPLC-UV	58.64%	6 davs	102
Micrococcus luteus N.ISM.1Gamma magnetic concurs luteus N.ISM.1Gamma magnetic constitutionGamma magnetic	6	Pseudomonas aeruoinosa	Dicloxacillin	30 °C 2 h	IIV PCR HPLC	100%	2.2 davs	103
Kebsielia sp.Diclofence sodium $30 \circ C_1$ 120 rpmLCMSLentinula edodes andCephalosporinUltrasound at 49 kHz, 20 minUPLC/MSLentinula edodesCascillinS8 $\circ C_1$ 140 rpmUPLC/MSLefoosphaerulina sp.Oxacillin28 $\circ C_1$ 140 rpmUPLCLefoosphaerulina sp.Oxacillin28 $\circ C_1$ 140 rpmUPLCLefoodesTrestostenone25 $\circ C \pm 2 \circ C_1$ 140 rpmUPLCLefoodesTrestostenone25 $\circ C \pm 2 \circ C_1$ 100 rpmUPLCLefoodesTropforence25 $\circ C \pm 2 \circ C_1$ 100 rpmUPLCPenicillium communeOxpetracycline25 $\circ C_1$ 29 $\circ C_1$ 100 rpmUPLCPenicillium conticumUPLC25 $\circ C_1$ 20 $\circ C_1$ 100 rpmHPLC, UV-SpecPenicillium conticumS5 $\circ C_1$ PH 6.0, 96 hHPLC, UV-SpecAddTrichoderma sp.Ciprofloxacin28 $\circ C_2$ 20 $\circ C_1$ 100 rpmAddTrichoderma sp.Ciprofloxacin28 $\circ C_2$ 20 $\circ C_1$ 100 rpm	10.	Micrococcus Intens N.ISM.1	Gahanentin	35 °C. 120 rnm. 72 h	FE-SEM. LC-ESI-MS	47%	40 days	104
Lentinula edodes and Inleria badiaCephalosporinUltrasound at 49 kHz, 20 minUPLC/MSInleria badiaCaecillin $38 \circ$ C, pH 5.6, and 160 pm for 15Biotransformation and daysLeptosphæerulina sp.Oxacillin $38 \circ$ C, pH 5.6, and 160 pm for 15Biotransformation and daysLeddesTestosterone $35 \circ$ C $\pm 2 \circ$ C, 140 pmUPLC, UPLCL. edodes 17σ -Ethinylestradiol $25 \circ$ C $\pm 2 \circ$ C, 100 pmUPLC, UPLCL. edodes 17σ -Ethinylestradiol $25 \circ$ C $\pm 2 \circ$ C, 100 pmUPLC, UPLCPenicillium oxalicumDiclofenac $28 \circ$ C, 120 rpmUPLC, UPLCPenicillium oxalicum RJJ-2Etythronycin $35 \circ$ C, pH 6.0, 96 hHPLC, UPLCAJAC3 $35 \circ$ C, pH 6.0, 96 hHPLC, UPLCAJAC3 17 -fb-estradiol (E2) $28 \circ$ C $\pm 2 \circ$ C, 120 rpmPinticrAMSAJAC3 $50 \circ$ C, pH 5.7Q-fb-fb-MS, SEM, FTIRAJAC3 $7 \circ$ C, pH 5.7Q-fb-fb-MS, SEM, FTIRAJAC3 $7 \circ$ C, pH 5.7Q-fb-fb-MS, SEM, FTIRAJAC3 $7 \circ$ C, pH 5.7Q-fb-MS, SEM, FTIRAJAC3Trichoderma s.p.CiprofoxacinAJAC3Trichoderma s.p.DiclofenacAJAC3Trichoderma s.p.CiprofoxacinAJAC3Trichoderma s.p.DiclofenacAJAC3Trichoderma s.p.DiclofenacAJAC3TrichodermUPLC, MS<	11. Fungus	Klebsiella sp.	Diclofenac sodium	30 °C, 120 rpm	TCMS	79.14%	3 days	105
Leptosphaerulina sp.Oxacillin $28 \circ_{\rm C}$, pH 5.6, and 160 rpm for 15Biotransformation and daysLedodesTestosterone $25 \circ_{\rm C} \pm 2 \circ_{\rm C}$, 140 rpmUPLCLedodes 172 -Ethinylestradiol $28 \circ_{\rm C}$, 130 rpmUPLCLedodes 172 -Ethinylestradiol $28 \circ_{\rm C}$, 130 rpmHPLC, UV-SpecPenicillium communeOxytetracycline $27 \circ_{\rm C}$, pH 7.3Optical and scanningPenicillium communeOxytetracycline $27 \circ_{\rm C}$, pH 7.3Optical and scanningPenicillium communeOxytetracycline $28 \circ_{\rm C}$, 130 rpmHPLC, UV-SpecTrichoderma citrinoviride 17 -β-estradiol (E2) $28 \circ_{\rm C}$, 146 rpmHPLC, GCMS, SEM, FTIRAlC3Trichoderma sp.Ciprofloxacin $27 \circ_{\rm C}$, pH 5.7Optical and scanningAlC3Trichoderma sp.Ciprofloxacin $28 \circ_{\rm C}$, 135 rpmPHLC, MSSAlC3Trichoderma sp.Ciprofloxacin $30 \circ_{\rm C}$, pH 5.7Q-Exactive-MS, RNAAlC3Trichoderma sp.Ciprofloxacin $30 \circ_{\rm C}$, pH 5.7Q-Exactive-MS, RNAPlanerochaeteSulfadiazine $30 \circ_{\rm C}$, pH 5.7Q-Exactive-MS, RNATrichoderma sp.Trichoderma sp.Ciprofloxacin $30 \circ_{\rm C}$, pH 5.7Chorella sp.FlortenicQ-Manuformacin 4 pH, 1 mL min ⁻¹ flow, 33 hChorella sp.FlortenicQ-Manuformacin 4 pH, 1 mL min ⁻¹ flow, 33 hChorella sp.Flortenicol 4 pH, 1 mL min ⁻¹ flow, 33 hQ-TOF LC/MSDial consortiumTrianetes versicolor 4	12.	Lentinula edodes and Imleria badia	Cephalosporin	Ultrasound at 49 kHz, 20 min	UPLC/MS	100%	7 days	106
L edodesTestosterone $25 \circ C \pm 2 \circ C$, 140 rpmUPLCL edodes $17a$ -Ethinylestradiol $25 \circ C \pm 2 \circ C$, 100 rpmHPLC, UV-Spec <i>Enticillium oxalicum</i> Diclofenae $28 \circ C$, 120 rpmHPLC, UV-Spec <i>Penicillium oxalicum</i> Diclofenae $28 \circ C$, 120 rpmHPLC, UV-Spec <i>Penicillium oxalicum</i> Diclofenae $28 \circ C$, 120 rpmHPLC, GCMS, SEM, FTIR <i>Penicillum oxalicum</i> Trichoderma citrinoviride 17 -fb-estradiol (E2) $28 \circ C$, 120 rpmHPLC, GCMS, SEM, FTIRAlAC3Trichoderma sp.Ciprofloxacin $25 \circ C$, 135 rpmHPLC, GCMS, SEM, FTIRAlAC3Trichoderma sp.Ciprofloxacin $25 \circ C$, 135 rpmLCMSAlAC3Trichoderma sp.Ciprofloxacin $25 \circ C$, 135 rpmLCMSAlAC3Trichoderma sp.Ciprofloxacin $25 \circ C$, 135 rpmLCMSAlAC3Trichoderma sp.Ciprofloxacin $25 \circ C$, 135 rpmPLC, GCMS, SEM, FTIRAlAC3Trichoderma sp.Ciprofloxacin $30 \circ C$, pH 5.7Q-Escutorems, RMAPlanerochaeteSulfadiazine $30 \circ C$, pH 5.7Q-Escutorems, RMAPlanerochaeteSulfadiazine $50 \circ C$, pH 5.7Q-Escutorems, RMAChlorella sp.Florencol $4 pH, 1 m m^{-1}$ flow, 33 hQ-TOF LC/MSChlorella sp.Florencol $4 pH, 1 m m^{-1}$ flow, 33 hQ-TOF LC/MSblaacontium-bacteria, fungus and yeast $6 \circ C, 120 rpm, 48 hPCRAlbedial pneumoniceOfloxacin30 \circ C, 120 rpm, 48 hPCRAlbedial pneumonice$	13.	Leptosphaerulina sp.	Oxacillin	28 °C, pH 5.6, and 160 rpm for 15 days	Biotransformation and MTT assay	100%	6 days	107
L edodes $17a$ -Bthinylestradiol $25 \circ C \pm 2 \circ C$, 100 rpmHPLC, UV-SpecPenicillium oxalicumDiclofenac $28 \circ C$, 120 rpmHPLC, UV-SpecPenicillium oxalicum BJ-2Exphromycin $27 \circ C$, pH 7.3Optical and scanningPenicillium oxalicum BJ-2Exphromycin $35 \circ C$, pH 6.0, 96 hHPLC, UV-SpecPenicillium oxalicum RJ-2Exphromycin $35 \circ C$, pH 6.0, 96 hHPLC, GCMS, SEM, FTIRAJAC3Trichoderma citrinoviride 17 -β-estradiol (E2) $28 \circ C$, 120 rpmHPLC, GCMS, SEM, FTIRAJAC3Trichoderma sp.Ciprofloxacin $28 \circ C$, 135 rpmHPLC, GCMS, SEM, FTIRAJAC3Trichoderma sp.Ciprofloxacin $30 \circ C$, pH 5.7Q-Exactive-MS, RNAAjAC3Trichoderma sp.Ciprofloxacin $30 \circ C$, pH 5.7Q-Exactive-MS, RNAPhaneorotaeteSulfadiazine $30 \circ C$, pH 5.7Q-Exactive-MS, RNATrametes versicolorDiclofenac $4 pH, 1 mL min^{-1} flow, 33 hQ-TOF LC/MSChlorella sp.Florfenicol600 \pm 100 lux illuminationHPLC-UVbial consortium—bacteria, fungus and yeast30 \circ C, 120 rpm, 48 hPCRAchromonice,Ofloxacin, and30 \circ C, 120 rpm, 48 hPCR$	14.	L. edodes	Testosterone	$25~{ m oC}\pm 2~{ m oC}$, 140 rpm	UPLC	100%	21 days	108
Penicillium oxalicumDiclofenac $28 \circ C_1 120 \text{ rpm}$ HPLC, UPLCPenicillium oxalicum RJI-2Etythromycline $27 \circ C_2 \text{ pH} 7.3$ Optical and scanningPenicillium oxalicum RJI-2Etythromycline $35 \circ C_1 \text{ pH} 6.0, 96 \text{ h}$ HPLC, UPLCPenicillium oxalicum RJI-2Etythromycline $35 \circ C_1 120 \text{ rpm}$ HPLC, GGMS, SEM, FTIRAjAC3Trichoderma citrinoviride 17 -β-estradiol (E2) $28 \circ C \pm 2 \circ C_1 120 \text{ rpm}$ HPLC, GGMS, SEM, FTIRAjAC3Trichoderma sp.Ciprofloxacin $35 \circ C_1 135 \text{ rpm}$ QCMS, SEM, FTIRAjAC3Trichoderma sp.Ciprofloxacin $30 \circ C_1 \text{ pH} 5.7$ Q-Exactive-MS, RNAPhanerochaeteSulfadiazine $30 \circ C_1 \text{ pH} 5.7$ Q-Exactive-MS, RNAPhanerochaeteSulfadiazine $30 \circ C_1 \text{ pH} 5.7$ Q-Exactive-MS, RNAPhanerochaeteSulfadiazine $30 \circ C_1 \text{ pH} 5.7$ Q-Evactive-MS, RNAPhanerochaeteSulfadiazine $30 \circ C_1 \text{ pH} 5.7$ Q-Evactive-MS, RNAPhanerochaeteSulfadiazine $30 \circ C_1 \text{ pH} 5.7$ Q-Evactive-MS, RNAChorella sp.Flortenicol $5000 \pm 100 \text{ lnx illumination}$ HPLC-UVbial consortium—bacteria, fungus and yeast $30 \circ C_1 120 \text{ rpm}, 48 \text{ h}$ PCRArbornbartersOflorenia, and $30 \circ C_1 120 \text{ rpm}, 48 \text{ h}$ PCR	15.	L. edodes	17α-Ethinylestradiol	$25~^{\circ}\mathrm{C}\pm2~^{\circ}\mathrm{C},100~\mathrm{rpm}$	HPLC, UV-Spec	100%	21 days	109
Penicillium communeOxytetracycline $27 ^{\circ}$ C, pH 7.3Optical and scanning electron microscopyPenicillium oxalicum RJJ-2Erythromycin $35 ^{\circ}$ C, pH 6.0, 96 hHPLC-MSTrichoderma citrinoviride 17 - β -estradiol (E2) $28 ^{\circ}$ C $\pm 2 ^{\circ}$ C, 120 rpmHPLC, GCMS, SEM, FTIRAJAC3Irrichoderma citrinoviride 17 - β -estradiol (E2) $28 ^{\circ}$ C $\pm 2 ^{\circ}$ C, 135 rpmHPLC, GCMS, SEM, FTIRAJAC3Irrichoderma sp.Ciprofloxacin $25 ^{\circ}$ C, 135 rpmLCMSAJAC3Irrichoderma sp.Ciprofloxacin $30 ^{\circ}$ C, pH 5.7Q-Exactive-MS, RNAPhanerochaeteSulfadiazine $30 ^{\circ}$ C, pH 5.7Q-Exactive-MS, RNA <i>chrysosporium</i> Irrametes versicolorDiclofenac $4 ^{\circ}$ H, 1 mL min ⁻¹ flow, 33 hQ-TOF LC/MS <i>Chlorella</i> sp.Florfenicolflydraulic retention time)HPLC-UVSequencingbial consortium—bacteria, fungus and yeast $30 ^{\circ}$ C, 120 rpm, 48 hV., HPLCAcheosicin and yeast $30 ^{\circ}$ C, 120 rpm, 48 hPCR	16.	Penicillium oxalicum	Diclofenac	28 °C, 120 rpm	HPLC, UPLC	100%	1 day	110
Penicillium oxalicum RJJ-2Erythromycin $35 \circ$ C, pH 6.0, 96 hHPLC-MSTrichoderma citrinoviride 17 -β-estradiol (E2) $28 \circ$ C ± 2 °C, 120 rpmHPLC, GCMS, SEM, FTIRAJAC3Trichoderma sp.Ciprofloxacin $25 \circ$ C, 135 rpmLCMSAJAC3Trichoderma sp.Ciprofloxacin $25 \circ$ C, 135 rpmLCMSTrichoderma sp.Ciprofloxacin $25 \circ$ C, 135 rpmQ-Exactive-MS, RNAPhanerochaeteSulfadiazine $30 \circ$ C, pH 5.7Q-Exactive-MS, RNATrametes versicolorDiclofenac $4 pH, 1 mL min^{-1}$ flow, 33 hQ-TOF LC/MSChlorella sp.Florfenicol $5000 \pm 100 lux illuminationHPLC-UVbial consortium—bacteria, fungus and yeast30 \circC, 120 rpm, 48 hPCRAchronoherer su offloxacin, and30 \circC, 120 rpm, 48 hPCR$	17.	Penicillium commune	Oxytetracycline	27 °C, pH 7.3	Optical and scanning electron microscopy	78%	15 days	111
Trichoderma citrinoviride 17 - β -estradiol (E2) $28 ^{\circ}$ C $\pm 2 ^{\circ}$ C, 120 rpmHPLC, GCMS, SEM, FTIRAJAC3Trichoderma sp.Ciprofloxacin $25 ^{\circ}$ C, 135 rpmLCMSPhanerochaeteSulfadiazine $30 ^{\circ}$ C, pH 5.7Q-Exactive-MS, RNAPhanerochaeteSulfadiazine $30 ^{\circ}$ C, pH 5.7Q-Exactive-MS, RNA <i>Phanerochaete</i> Sulfadiazine $30 ^{\circ}$ C, pH 1 mL min ⁻¹ flow, 33 hQ-TOF LC/MS <i>Chronelas</i> Diclofenac 4pH , 1 mL min ⁻¹ flow, 33 hQ-TOF LC/MS <i>Chorella</i> sp.Florfenicol $500 \pm 100 \text{lux illumination}$ HPLC-UVbial consortium—bacteria, fungus and yeast $30 ^{\circ}$ C, 120 rpm, 48 hPCR <i>Achnonohaere</i> Onfoxacin, and $30 ^{\circ}$ C, 120 rpm, 48 hPCR	18.	Penicillium oxalicum RJJ-2	Erythromycin	35 °C, pH 6.0, 96 h	HPLC-MS	84%	4 days	112
Trichoderma sp.Ciprofloxacin $25 ^{\circ}$ C, 135 rpmLCMSPhanerochaeteSulfadiazine $30 ^{\circ}$ C, pH 5.7Q-Exactive-MS, RNAchrysosporiumSulfadiazine $30 ^{\circ}$ C, pH 5.7Q-Exactive-MS, RNAchrysosporiumSulfadiazine $30 ^{\circ}$ C, pH 5.7Q-Exactive-MS, RNAtrametes versicolorDiclofenac4 pH, 1 mL min ⁻¹ flow, 33 hQ-TOF LC/MSChlorella sp.Florfenicol $5000 \pm 100 \text{lux illumination}$ HPLC-UVbial consortium—bacteria, fungus and yeast $4 ^{\circ}$ C, 5000 rpm, 10 minUv, HPLCAchromoherer sn Canidanorthoracin, and $30 ^{\circ}$ C, 120 rpm, 48 hPCR	19.	Trichoderma citrinoviride AJAC3	17-β-estradiol (E2)	$28~^{\circ}\mathrm{C}\pm2~^{\circ}\mathrm{C}$, $120~\mathrm{rpm}$	HPLC, GCMS, SEM, FTIR	100%	4 days	113
PhanerochaeteSulfadiazine $30 ^{\circ}$ C, pH 5.7Q-Exactive-MS, RNAchrysosporiumchrysosporiumsequencingTrametes versicolorDiclofenac4 pH, 1 mL min ⁻¹ flow, 33 hQ-TOF LC/MSChlorella sp.Florfenicol $(hydraulic retention time)$ PPLC-UVChlorella sp.Florfenicol $5000 \pm 100 \ln x$ illuminationHPLC-UVbial consortium—bacteria, fungus and yeast $4 ^{\circ}$ C, 5000 rpm, 10 minUv, HPLCbial consortium—bacteria, fungus and yeast $30 ^{\circ}$ C, 120 rpm, 48 hPCR	20.	Trichoderma sp.	Ciprofloxacin	25 °C, 135 rpm	LCMS	81%	13 days	114
Tranete versicolorDiclofenac4 pH, 1 mL min ⁻¹ flow, 33 hQ-TOF LC/MSTranetes versicolorDiclofenac4 pH, 1 mL min ⁻¹ flow, 33 hQ-TOF LC/MSChlorella sp.Florfenicol5000 \pm 100 lux illuminationHPLC-UVChlorella sp.Thiamphenicol5000 \pm 100 lux illuminationHPLC-UVbial consortium—bacteria, fungus and yeast4 °C, 5000 rpm, 10 minUv, HPLCAchromohacter sn Candidanorfloxacin, and30 °C, 120 rpm, 48 hPCR	21.	Phanerochaete chrvsosporium	Sulfadiazine	30 °C, pH 5.7	Q-Exactive-MS, RNA sequencing	100%	6 days	115
Chlorella sp.Florfenicol $5000 \pm 100 \text{ lux illumination}$ HPLC-UVChlorella sp.Thiamphenicol $4 ^{\circ}\text{C}$, 5000 rpm , 10 min Uv, HPLCbial consortium—bacteria, fungus and yeast $30 ^{\circ}\text{C}$, 120 rpm , 48 h PCRAchromotacter sn.Candidanorthoracin 48 h	22.	Trametes versicolor	Diclofenac	4 pH, 1 mL min ⁻¹ flow, 33 h (hydraulic retention time)	Q-TOF LC/MS	98%	7 days	116
Chlorella sp. Thiamphenicol 4 °C, 5000 rpm, 10 min Uv, HPLC crobial consortium—bacteria, fungus and yeast 4 °C, 5000 rpm, 10 min Uv, HPLC <i>Klebsiella pneumoniae</i> , Ofloxacin, and 30 °C, 120 rpm, 48 h PCR <i>A chromohacter</i> sn. <i>Candida</i> northoxacin, and 30 °C, 120 rpm, 48 h PCR	Algea 23.	Chlorella sp.	Florfenicol	5000 ± 100 lux illumination intensity $30 + 1$ °C	HPLC-UV	97%	7 days	117
cin, and 30 °C, 120 rpm, 48 h PCR	24. Microhial	Chlorella sp. concortium_bacteria_finonic ar	Thiamphenicol	4 °C, 5000 rpm, 10 min	Uv, HPLC	97%	5 days	118
	1/11/1/0/141	VOIISOLUUIIIT—Vacuuta, tuuguo u Klehsiella nneumoniae	nu yeası Ofloxacin, and	30 °C 120 mm 48 h	рСВ	8.0%	2.0 davs	119
	.04	Achromobacter sp., Candida	norfloxacin	10 00 110 1 10 10 10 00		0/ 00	40 mm	-

Achromobacter sp., Candida manassasensis, Trichosporon asahii

or rises four times for every 10 °C temperature increase. The temperature is directly related to the operation of cell enzymes and cell membranes. High temperatures cause protein denaturation, whereas low temperatures affect the cell viscosity and stiffness, limiting the enzyme performance. Temperature has also been shown to have a considerable impact on the metabolic development and activity of cultures.122-124 In a study by Yu et al.,¹²⁵ the effect of different parameters on sulfamethoxazole degradation by Pseudomonas koreensis and Paenarthrobacter ureafaciens was analysed. The effects of temperatures ranging from 10 to 50 °C have been investigated. The bacterial consortium grew better at temperatures ranging from 20 to 40 degrees Celsius. The ideal temperature for maximum sulfamethoxazole was found to be 30 °C. Microbial development was not possible at low temperatures. Similarly, no pharmacological decrease was observed at high temperatures.125

Microbial inoculum is a key aspect in the degradation of medicinal substances. When the inoculum is large, it can occasionally hinder the degrading capacity due to poisonous material release. The ageing of the inoculum affects the organism's ability to degrade.126 Yang et al.97 studied the impact of several parameters on the degradation of chloramphenicol by Pseudomonas and Shewanella sp. For maximum breakdown ability, bacterial inoculation amounts of 1, 2, and 3% were changed. The effectiveness of biodegradation increased, as the bacterial count increased from 1% to 2%. Yet, at 3% bacterial concentration, the degradation remains steady without further rise. At a bacterial load of 2%, a maximum of 60-65% degradation efficiency was achieved.98 The nature and characteristics of medicinal compounds play an additional role in biodegradation. The more stable and complex pharmacological substances are more difficult to breakdown.127

4. Recent advancements

4.1 Metabolic or genetic engineering

Genetic and metabolic engineering is a rapidly growing discipline globally for the production of novel microbes with desired features. In general, genetically modified organisms are bacteria that have had their genetic code altered via the recombinant DNA process. Designing genetic and metabolically modified organisms is required for creating new metabolism pathways for pharmaceutical degradation, reducing hazardous metabolite accumulation, increasing metabolic catabolism, and improving organism substrate flux. The introduction of novel genes aids in the adaptation of microorganisms to pharmaceutical pollutants.128,129 The steps involved in the production of metabolically engineered microbes are shown in Fig. 3. The recombinant DNA field enables improved energy generating methods, increased copy number, and inclusion of desired genes. The metabolic engineering method has included novel aspects relevant to limiting factors and pathways. Various genetic methods have been used to reinforce optimal gene expression and change the metabolic pathways of enzymes.130 Some fundamental elements must be present in order to regulate the complicated enzyme system and metabolism. Four parameters must be observed when it comes to the breakdown of pharmaceutical contaminants: enzyme nature, metabolic management of the breakdown pathway, creation with metabolic pathway regulation, and lastly, overall process development for improved genetic modification. Fungal genetic engineering plays a significant role in modifying enzyme targets and affinity for medicinal drugs.131,132

Another new subject that offers potential solutions for pharmaceutical degradation is metabolic engineering. *In vitro*




Fig. 3 Steps involved in the production of metabolically engineered microbes.

and in vivo approaches are used to create a synthetic metabolic pathway. In silico technologies can be used to anticipate probable metabolic pathway paths. Another emerging subject is enzyme engineering, which involves the development of novel enzymes with activating/deactivating roles in the metabolic breakdown pathway.^{133,134} Aulestia et al.¹³⁵ applied genetic characterisation to determine the metabolic pathway for ibuprofen degradation in a recent research study. Rhizorhabdus wittichii eliminates the pharmaceutical pollutant ibuprofen by the generation of metabolites. Genetic approaches have been used to identify IBU genes with non-colored and leaky mutants. For a better understanding of pathways, molecular biology methods such as mutant insertion and sequence analysis were used.135 A research study employed Escherichia coli metabolic engineering to complete naphthalene breakdown. A total of 17 genes involved in the degradation pathway were optimized and rebuilt. It is possible to recreate the metabolic modules involved in the conversion of naphthalene into catechol and other metabolites. In that study, consecutive naphthalene degradation was achieved by altering the BL-CA-cat genes.¹³⁶ Similarly, recent studies have focused on the genetic and metabolic alteration of microbial species for improved pharmaceutical contaminant breakdown.

4.2 Immobilization

Enzymes play a crucial role in the microbial breakdown of medications by metabolising the complex compounds. These enzymes can be used directly to degrade the substances. The enzymes can be introduced into the degradation medium as free cells or immobilized. Because enzymes in their free state are difficult to separate, they can be immobilized into solid support materials that only enable the transfer of degrading chemicals into it.^{137,138} The immobilization procedure will also considerably

increase the enzymes' stability and reusability. The two ways for immobilizing enzymes onto solid substrates are physical and chemical. Chemical approaches include cross-linking and covalent bonding, whereas physical methods include encapsulation, entrapment, and adsorption. Physical or ionic attachment of enzymes to solid supports is one way of immobilization via adsorption. Fig. 4 denotes the microbial immobilization for the removal of pharmaceutical pollutants. Silica gel, activated carbon, porous glass, biomass, and other organic porous substances are the commonly utilized support materials.139,140 Because adsorption does not necessitate the use of expensive materials, enzyme or cell structure will not be altered, resulting in high enzymatic activity. Encapsulation encompasses immobilizing enzymes in a spherical shaped non-permeable membrane, whereas entrapment involves enclosing enzymes or cells in a closed fiber-like network. Because physical trapping of enzymes is sometimes ineffective, resulting in enzyme leakage, chemical methods of immobilization are used. Partially deformed enzyme structures and molecular networks produce a stable and strong bond with the support matrix. Chemical immobilisation techniques such as covalent, disulphide, and ionic bonding allow many treatment and reuse cycles.141-143

Cross linking is another type of immobilisation in which enzymes can be immobilised as crystals or aggregates. Primozic *et al.*¹⁴⁴ immobilised a laccase enzyme as a cross-linked aggregate for diclofenac biodegradation. Laccase precipitation in propanol and aminosilane magnetic nanoparticle solutions was used to form the aggregates. The degradation process was carried out in a stirred batch reactor. The ability to remove diclofenac was approximately 13–16 g diclofenac/g laccase. Even after the fourth regeneration cycle, the immobilised enzyme's half-life remained constant. Immobilised laccases also exhibit good stability.¹⁴⁴ Laccase was immobilised in a polyvinylidene fluoride




Fig. 4 Microbial immobilization for the removal of pharmaceutical pollutants.

nanocomposite and nanotube containing diclofenac and carbamazepine for breakdown in another recent investigation by Masjoudi et al.141 Initially, phase inversion was used to create multiwalled carbon nanotubes using polyvinylidene fluoride nanocomposites. The laccase enzyme was immobilised in the produced samples and used as a catalyst in pharmaceutical degradation. In the membrane reactor, an activity recovery of 38.31% was recorded with immobilised laccase, with a removal efficiency of 27%.141 Whole cells can also be immobilised for pharmacological degradation. Zur et al.145 immobilised the entire Pseudomonas moorei strain in bacterial cellulose for degrading purposes. Immobilisation was performed for 72 hours in order to improve its effectiveness, and it was examined for auto aggregation and co-aggregation capacity. This complete cell immobilised system decomposed around 150 mg L^{-1} of paracetamol. Hydroquinone 1,2-dioxygenase, deaminase, and acyl amidohydrolase are major enzymes implicated in the paracetamol breakdown route via entire immobilisation.145 As a result, an immobilised enzyme system with reusable capacity can be successfully used for pharmaceutical degradation.

5. Microbial degradation: kinetic models

The kinetics section is critical for determining the breakdown of pharmaceutical contaminants. Microbial degradation kinetics aids in the accurate evaluation of microorganisms and their environments for pollutant degradation. Besides, model building is critical in regulatory considerations for predicting biodegradation at different time intervals. For the microbe-based degradation of pharmaceutical contaminants, many kinetic models have been developed.¹⁴⁶⁻¹⁴⁸ One such model for determining degradation kinetics is the Haldane equation. This equation addresses the kinetics of cell development on hazardous substrates. The Haldane equation can be represented as follows:¹⁴⁹

$$\mu = \frac{\mu_{\max} S_0}{K_{\rm S} + S_0 + \left(\frac{S_0^2}{K_{\rm i}}\right)}$$
(1)

When the inhibition phenomenon occurs, the Haldane equation is more appropriate. The significant parameters are max, $K_{\rm S}$, and $K_{\rm i}$. Certain investigations show that low values of max are due to low biomass concentrations. At high pharmacological concentrations, substrate inhibition can occur, resulting in the incomplete mineralization of intermediates.¹⁵⁰ Calero-Diaz *et al.*¹⁵¹ used kinetic modelling analysis to better understand the biodegradation of ibuprofen, ciprofloxacin, and carbamazepine in a membrane bioreactor system. The following equation was used in the investigation to determine the decay coefficient and kinetics.

$$b_{\rm H} = \frac{k_{\rm d}}{1 - Y_{\rm H}(1 - f_{\rm P})} \tag{2}$$

where the decay efficient is represented by $b_{\rm H}$ and the volatile biomass fraction is denoted by the term $1 - f_{\rm P}$. The addition of pharmaceuticals ibuprofen, ciprofloxacin, and carbamazepine to the membrane bioreactor system resulted in a higher biodegradation rate, which doubled as the cell growth rate increased. With various pharmacological concentrations and an average decay rate of 1–80 g (h^{-1} mg⁻¹), 83–100% elimination was obtained.¹⁵¹ In addition to the proposed models, the pseudo-first-order kinetic model is a commonly utilised technique of pharmacological degradation. In the first-order kinetics, the reaction rate can be calculated and is proportional to the change in initial pharmaceutical concentration with time. Ciprofloxacin biodegradation has also been studied in another study using *Thermus* sp. A bacterium that degrades pharmaceuticals has been identified from the pharmaceutical sludge. The linear relationship between time and diminishing medication concentration can be described as follows:

$$\ln C_t = -kt + \ln C_0 \tag{3}$$

The first-order kinetic model agreed well with the experimental data, indicating that microorganisms were responsible for the majority of the deterioration. Sodium acetate increased *Thermus* sp. biomass production by acting as an electron donor in the non-growth factor metabolism.¹⁵² As a result, various kinetic models have been created and confirmed by researchers based on their research.

6. Future outlooks and challenges

One of the key challenges facing pharmaceutical microbial degradation is the lack of standard methodologies for assessing and comparing the degrading ability of different microbial species. Some typical biodegrading analysis methods are inaccurate, which have to be investigated further. The presence of many pollutants in the system reduces the degrading ability. The effect of antibiotics, for example, on the pharmaceutical transport behaviour is critical for successful clearance. This effect's hazy concept needs to be researched further. To anticipate the optimum period for degradation, the microbial species' adaptation time to the pharmaceutical wastewater environment must be well characterised. The mineralization process mostly degrades pharmaceutical substances. However, certain microorganisms biotransform pharmaceutical components, producing intermediates that are more dangerous than the primary pollutants. As a result, a mixed microbial consortium might be used for complete pollutant mineralization rather than a single pure culture, which lacks this potential. The utilisation of extra substrates, which aids in biodegradation via cometabolic processes, can also improve the biodegradation efficiency. The adoption of optimum statistical approaches can improve the growth conditions of microbial cultures. The incorporation of statistics and bioinformatics fields facilitates process condition optimisation. While the subject of genetic engineering has been developed for the alteration of microbial strains to aid in enhanced biodegradation processes, there is a dearth of research studies focusing on this issue. As a result, the scope of genetic engineering should be properly studied, and pathways should be clarified. To gain a better

understanding, various biodegradation routes used by microorganisms must be precisely identified. The reusability of enzymes or entire cells involved in the pharmaceutical degradation process can now be achieved because of the recent advances in immobilisation. However, some mass transfer constraints impact the movement of intermediates and metabolites into and out of the immobilised support system. The discovery of microbial degradation pathways enables modern developments such as metabolic or genetic engineering and immobilisation to significantly increase pharmaceutical biodegradation. A few numbers of kinetic investigations on pharmaceutical biodegradation have been conducted. As a result, additional research incorporating other process parameters is required for a better prediction of degradation rate and kinetic mechanism.

7. Conclusion

Substantial progress in the field of microbial remediation has been the focus in recent years. The presence of microbial communities determines the capacity and efficiency with which medicinal substances can be destroyed. Persistent pharmaceutical pollutants in the environment can be minimised via several metabolic and co-metabolic transformation processes. Hydrolysis and bio-oxidation are the two major degradation pathways for the microbe-mediated pharmaceutical remediation. The use of mixed microbial cultures is desirable for improving THE biodegradation activity. Advanced statistical and bioinformatics tools have been used to optimize the factors impacting the microbial degradation process. The advancement of immobilization techniques with various solid supports improves the reusability of materials used in the remediation processes. The ideal support systems should overcome the mass transfer constraint in the immobilised system. The field of metabolic and genetic engineering is a recent development in the microbial breakdown of pharmaceutical contaminants. Metabolic engineering approaches aid in developing new degradation pathways of metabolism, which enhance the ecological pharmaceutical removal. Of the different kinetic models facilitating the selection of several optimum techniques for polluted sites, the pseudofirst-order model is the best suited due to its better coherence with the process conditions. The future prospects for enzyme engineering improve the aspect of pharmaceutical degradation. Novel in silico techniques in the metabolic engineering field could enhance the contaminant removal from the ecosystem.

Conflicts of interest

There are no conflicts to declare.

References

1 Y. Huang, S. F. Chen, W.-J. Chen, X. Zhu, S. Mishra, P. Bhatt and S. Chen, Efficient biodegradation of multiple pyrethroid pesticides by *Rhodococcus pyridinivorans* strain Y6 and its degradation mechanism, *Chem. Eng. J.*, 2023, **469**, 143863, DOI: **10.1016/j.cej.2023.143863**.

- 2 A. Sengar and A. Vijayanandan, Human health and ecological risk assessment of 98 pharmaceuticals and personal care products (PPCPs) detected in Indian surface and wastewaters, *Sci. Total Environ.*, 2022, **807**, 150677, DOI: **10.1016/j.scitotenv.2021.150677**.
- 3 N. Das, J. Madhavan, A. Selvi and D. Das, An overview of cephalosporin antibiotics as emerging contaminants: a serious environmental concern, *Biotech*, 2019, **9**, 231, DOI: **10.1007/s13205-019-1766-9**.
- 4 K. Samal, S. Mahapatra and M. H. Ali, Pharmaceutical wastewater as Emerging Contaminants (EC): Treatment technologies, impact on environment and human health, *Energy Nexus*, 2022, **6**, 100076, DOI: **10.1016**/ **j.nexus.2022.100076**.
- 5 B. K. Zaied, M. Rashid, M. Nasrullah, A. W. Zularisam, D. Pant and L. Singh, A comprehensive review on contaminants removal from pharmaceutical wastewater by electrocoagulation process, *Sci. Total Environ.*, 2020, 726, 138095, DOI: 10.1016/j.scitotenv.2020.138095.
- 6 H. K. Khan, M. Y. A. Rehman and R. N. Malik, Fate and toxicity of pharmaceuticals in water environment: An insight on their occurrence in South Asia, *J. Environ. Manage.*, 2020, 271, 111030, DOI: 10.1016/ j.jenvman.2020.111030.
- 7 W.-J. Chen, W. Zhang, Q. Lei, S. F. Chen, Y. Huang, K. Bhatt, L. Liao and X. Zhou, *Pseudomonas aeruginosa* based concurrent degradation of beta-cypermethrin and metabolite 3-phenoxybenzaldehyde, and its bioremediation efficacy in contaminated soils, *Environ. Res.*, 2023, 236, 116619, DOI: 10.1016/j.envres.2023.116619.
- 8 P. Bhatt, K. Bhatt, A. Sharma, W. Zhang, S. Mishra and S. Chen, Biotechnological basis of microbial consortia for the removal of pesticides from the environment, *Crit. Rev. Biotechnol.*, 2021, **41**, 317–338, DOI: **10.1080**/ **07388551.2020.1853032**.
- 9 E. S. Okeke, T. P. C. Ezeorba, C. O. Okoye, Y. Chen, G. Mao, W. Feng and X. Wu, Environmental and health impact of unrecovered API from pharmaceutical manufacturing wastes: A review of contemporary treatment, recycling and management strategies, *Sustainable Chem. Pharm.*, 2022, 30, 100865, DOI: 10.1016/j.scp.2022.100865.
- 10 D. Lobato-Peralta, E. Duque-Brito, A. Ayala-Cortés, D. M. Arias, A. Longoria, A. K. Cuentas-Gallegos, P. J. Sebastian and P. U. Okoye, Advances in activated carbon modification, surface heteroatom configuration, reactor strategies, and regeneration methods for enhanced wastewater treatment, *J. Environ. Chem. Eng.*, 2021, 9, 105626, DOI: 10.1016/j.jece.2021.105626.
- 11 M. A. Tufail, J. Iltaf, T. Zaheer, L. Tariq, M. B. Amir, R. Fatima, A. Asbat, T. Kabeer, M. Fahad, H. Naeem, U. Shoukat, H. Noor, M. Awais, W. Umar and M. Ayyub, Recent advances in bioremediation of heavy metals and persistent organic pollutants: A review, *Sci. Total Environ.*, 2022, **850**, 157961, DOI: 10.1016/j.scitotenv.2022.157961.
- 12 P. R. Rout, T. C. Zhang, P. Bhunia and R. Y. Surampalli, Treatment technologies for emerging contaminants in

wastewater treatment plants: A review, *Sci. Total Environ.*, 2020, 753, 141990, DOI: 10.1016/j.scitotenv.2020.141990.

- 13 F. Khalid, M. Z. Hashmi, N. Jamil, A. Qadir and M. I. Ali, Microbial and enzymatic degradation of PCBs from ewaste-contaminated sites: a review, *Environ. Sci. Pollut. Res.*, 2021, 28, 10474–10487, DOI: 10.1007/s11356-020-11996-2.
- 14 A. Silva, C. Delerue-Matos, S. A. Figueiredo and O. M. Freitas, The Use of Algae and Fungi for Removal of Pharmaceuticals by Bioremediation and Biosorption Processes: A Review, *Water*, 2019, **11**, 1555, DOI: **10.3390**/ **w11081555**.
- 15 S. F. Chen, W.-J. Chen, Y. Huang, M. Wei and C. Chang, Insights into the metabolic pathways and biodegradation mechanisms of chloroacetamide herbicides, *Environ. Res.*, 2023, 229, 115918, DOI: 10.1016/j.envres.2023.115918.
- 16 F. Ansari, A. Momina, A. Ahmad and M. Rafatullah, Review on bioremediation technologies of polycyclic aromatic hydrocarbons (PAHs) from soil: Mechanisms and future perspective, *Int. Biodeterior. Biodegrad.*, 2023, **179**, 105582, DOI: **10.1016/j.ibiod.2023.105582**.
- M. N. Abbasi, J. Fu, X. Bian, H. Wang, Y. Zhang and A. Li, Recombineering for Genetic Engineering of Natural Product Biosynthetic Pathways, *Trends Biotechnol.*, 2020, 38, 715–728, DOI: 10.1016/j.tibtech.2019.12.018.
- 18 P. Patra, M. Das, P. Kundu and A. Ghosh, Recent advances in systems and synthetic biology approaches for developing novel cell-factories in non-conventional yeasts, *Biotechnol. Adv.*, 2021, 47, 107695, DOI: 10.1016/ j.biotechadv.2021.107695.
- 19 E. Sagir and S. Alipour, Photofermentative hydrogen production by immobilized photosynthetic bacteria: Current perspectives and challenges, *Renewable Sustainable Energy Rev.*, 2021, 141, 110796, DOI: 10.1016/ j.rser.2021.110796.
- 20 R. A. Sheldon, A. Basso and D. Brady, New frontiers in enzyme immobilisation: robust biocatalysts for a circular bio-based economy, *Chem. Soc. Rev.*, 2021, **50**, 5850–5862, DOI: **10.1039/D1CS00015B**.
- 21 A. Rahmani, M. Salari, K. Tari, A. Shabanloo, N. Shabanloo and S. Bajalan, Enhanced degradation of furfural by heatactivated persulfate/nZVI-rGO oxidation system; Degradation pathway and improving the biodegradability of oil refinery wastewater, *J. Environ. Chem. Eng.*, 2020, **8**, 104468, DOI: **10.1016/j.jece.2020.104468**.
- 22 M. A. Garcia, M. B. Bolger, S. Suarez-Sharp and P. Langguth, Predicting pharmacokinetics of multisource acyclovir oral products through physiologically based biopharmaceutics modeling, *J. Pharm. Sci.*, 2022, **111**, 262–273, DOI: **10.1016/j.xphs.2021.10.013**.
- 23 G. Wang, R. Chen, P. Huang, J. Hong, J. Cao, Q. Wu, W. Zheng, L. Lin, Q. Han, Y. Chen and N. Xia, Adefovir dipivoxil efficiently inhibits the proliferation of pseudorabies virus in vitro and in vivo, *Antiviral Res.*, 2021, 186, 105014, DOI: 10.1016/j.antiviral.2021.105014.
- 24 W. Danysz, A. Dekundy, A. Scheschonka and P. Riederer, Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials, *J. Neural*

Transm., 2021, **128**, 127–169, DOI: **10.1007/s00702-021-02306-2**.

- 25 J. Rajeev, K. Kamalasanan, H. Sapa, M. Sabitha and C. Abhi, Controlled release nanomedicine (CRNM) of aspirin using "biomimetic niosomal nanoparticles (BNNs)" for Covid-19 and cardiovascular treatment: DOE based optimization, *OpenNano*, 2023, 9, 100119, DOI: 10.1016/ j.onano.2022.100119.
- 26 A. Newman, S. M. Reutzel-Edens and G. Zografi, Coamorphous active pharmaceutical ingredient–small molecule mixtures: considerations in the choice of coformers for enhancing dissolution and oral bioavailability, *J. Pharm. Sci.*, 2018, **107**, 5–17, DOI: **10.1016/j.xphs.2017.09.024**.
- 27 K. Dolle and Q. Wang, Application of subsurface bioreactor for wastewater treatment, *Int. J. Earth Environ. Sci.*, 2017, 2, 1–6, DOI: 10.15344/2456-351X/2017/132.
- 28 M. L. Tkachenko, M. A. Loseva, L. E. Zhnyakina and A. V. Lyamin, Binary Medicinal System: Antiinflammatory Activity Of The Binary Eutectic System, *Probl. Biol., Med. Pharm. Chem.*, 2021, 24, 35–41, DOI: 10.29296/25877313-2021-02-06.
- 29 P. Saxena, P. K. Sharma and P. Purohit, A journey of celecoxib from pain to cancer, *Prostaglandins Other Lipid Mediators*, 2020, **147**, 106379, DOI: **10.1016**/ j.prostaglandins.2019.106379.
- 30 R. R. Tjandrawinata, A. Setiawati, D. Nofiarny, L. W. Susanto and E. Setiawati, Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib, *Clin. Pharmacol.*, 2018, **10**, 43–51, DOI: **10.2147/CPAA.S161024**.
- 31 A. Mansoori, F. Zahednezhad, A. Bavili Tabrizi and J. Shahbazi Mojarrad, Development of a new synthesis approach for S-pregabalin by optimizing the preparation stages, *J. Iran. Chem. Soc.*, 2020, **17**, 89–101, DOI: **10.1007**/**s13738-019-01759-3**.
- 32 L. Gaohua, X. Miao and L. Dou, Crosstalk of physiological pH and chemical pK_a under the umbrella of physiologically based pharmacokinetic modeling of drug absorption, distribution, metabolism, excretion, and toxicity, *Expert Opin. Drug Metab. Toxicol.*, 2021, **17**, 1103–1124, DOI: **10.1080/17425255.2021.1951223**.
- 33 H. Nabizadeh, A. Mohammadi, R. Dolatabadi, S. Nojavan and F. Vahabizad, Sensitive determination of ethosuximide in human fluids by electromembrane extraction coupled with high performance liquid chromatography ultraviolet spectroscopy, *J. Chin. Chem. Soc.*, 2023, **70**, 76–86, DOI: **10.1002/jccs.202200423**.
- 34 J. Choi, D. Yoon, M. Park, K. I. Joung and J. Y. Shin, Topiramate-related adverse events: Pattern and signals in the Korea Adverse Event Reporting System, 2010-2017, *Medicine*, 2020, 99, e22669, DOI: 10.1097/ MD.000000000022669.
- 35 S. K. Ettaboina, L. N. R. Katakam and T. Dongala, Development and validation of a stability-indicating RP-HPLC method for the determination of erythromycin related impurities in topical dosage form, *Pharm. Chem. J.*, 2022, **56**, 131–137, DOI: **10.1007/s11094-022-02610-5**.

- 36 R. Zhuan and J. Wang, Degradation of sulfamethoxazole by ionizing radiation: Kinetics and implications of additives, *Sci. Total Environ.*, 2019, 668, 67–73, DOI: 10.1016/ j.scitotenv.2019.03.027.
- 37 F. Y. S. Kong, P. Horner, M. Unemo and J. S. Hocking, Pharmacokinetic considerations regarding the treatment of bacterial sexually transmitted infections with azithromycin: a review, *J. Antimicrob. Chemother.*, 2019, 74, 1157–1166, DOI: 10.1093/jac/dky548.
- 38 J. Berges, S. Moles, M. P. Ormad, R. Mosteo and J. Gómez, Antibiotics removal from aquatic environments: adsorption of enrofloxacin, trimethoprim, sulfadiazine, and amoxicillin on vegetal powdered activated carbon, *Environ. Sci. Pollut. Res.*, 2021, 28, 8442–8452, DOI: 10.1007/s11356-020-10972-0.
- 39 S. Ghimire, B. Maharjan, E. M. Jongedijk, J. G. Kosterink, G. R. Ghimire, D. J. Touw, T. S. van der Werf, B. Shrestha and J. W. C. Alffenaar, Evaluation of saliva as a potential alternative sampling matrix for therapeutic drug monitoring of levofloxacin in patients with multidrugresistant tuberculosis, *Antimicrob. Agents Chemother.*, 2019, **63**, e0237918, DOI: **10.1128/aac.02379-18**.
- 40 D. Dixit, P. Thanekar and V. M. Bhandari, Dual activity cavitation reactors for increased efficacy in degradation of refractory pollutants-A case study on cephalexin degradation, *Chem. Eng. Res. Des.*, 2023, **192**, 310–322, DOI: **10.1016/j.cherd.2023.02.037**.
- 41 R. Pratiwi, E. Noviana, R. Fauziati, D. B. Carrão, F. A. Gandhi, M. A. Majid and F. A. Saputri, A review of analytical methods for codeine determination, *Molecules*, 2021, **26**, 800, DOI: **10.3390/molecules26040800**.
- 42 G. Del Vecchio, D. Labuz, J. Temp, V. Seitz, M. Kloner, R. Negrete, A. Rodriguez-Gaztelumendi, M. Weber, H. Machelska and C. Stein, pK_a of opioid ligands as a discriminating factor for side effects, *Sci. Rep.*, 2019, 9, 1–9, DOI: 10.1038/s41598-019-55886-1.
- 43 T. W. Hale and K. Krutsch, Opioid use in breastfeeding mothers and neonatal risks, *Clin. Pharmacol. Ther.*, 2021, 109, 573–575, DOI: 10.1002/cpt.2118.
- 44 B. M. Kapur and K. Aleksa, What the lab can and cannot do: clinical interpretation of drug testing results, *Crit. Rev. Clin. Lab. Sci.*, 2020, 57, 548–585, DOI: 10.1080/ 10408363.2020.1774493.
- 45 E. Naghdi and A. R. Fakhari, Simultaneous chiral separation of tramadol and methadone in tablets, human urine, and plasma by capillary electrophoresis using maltodextrin as the chiral selector, *Chirality*, 2018, **30**, 1161–1168, DOI: **10.1002/chir.23008**.
- 46 S. L. Badshah, S. Faisal, A. Muhammad, B. G. Poulson, A. H. Emwas and M. Jaremko, Antiviral activities of flavonoids, *Biomed. Pharmacother.*, 2021, **140**, 111596, DOI: **10.1016/j.biopha.2021.111596**.
- 47 C. Nannou, A. Ofrydopoulou, E. Evgenidou, D. Heath, E. Heath and D. Lambropoulou, Antiviral drugs in aquatic environment and wastewater treatment plants: A review on occurrence, fate, removal and ecotoxicity, *Sci. Total*

Environ., 2020, **699**, 134322, DOI: **10.1016**/ **j.scitotenv.2019.134322**.

- 48 M. Hutchings, A. Truman and B. Wilkinson, Antibiotics: past, present and future, *Curr. Opin. Microbiol.*, 2019, **51**, 72–80, DOI: **10.1016/j.mib.2019.10.008**.
- 49 J. Murugaiyan, P. A. Kumar, G. S. Rao, K. Iskandar, S. Hawser, J. P. Hays, Y. Mohsen, S. Adukkadukkam, W. A. Awuah, R. A. M. Jose, *et al.*, Progress in Alternative Strategies to Combat Antimicrobial Resistance: Focus on Antibiotics, *Antibiotics*, 2022, **11**, 200, DOI: **10.3390**/ **antibiotics11020200**.
- 50 P. Krasucka, B. Pan, Y. Sik Ok, D. Mohan, B. Sarkar and P. Oleszczuk, Engineered biochar - A sustainable solution for the removal of antibiotics from water, *Chem. Eng. J.*, 2020, **405**, 126926, DOI: **10.1016/j.cej.2020.126926**.
- 51 N. K. Panchal and E. P. Sabina, Non-steroidal antiinflammatory drugs (NSAIDs): A current insight into its molecular mechanism eliciting organ toxicities, *Food Chem. Toxicol.*, 2023, **172**, 113598, DOI: **10.1016**/ **j.fct.2022.113598**.
- 52 S. Bindu, S. Mazumder and U. Bandyopadhyay, Nonsteroidal anti-inflammatory drugs (NSAIDs) and organ damage: a current perspective, *Biochem. Pharmacol.*, 2020, 180, 114147, DOI: 10.1016/j.bcp.2020.114147.
- 53 R. Pal, B. Kumar, M. J. Akhtar and P. A. Chawla, Voltage gated sodium channel inhibitors as anticonvulsant drugs: A systematic review on recent developments and structure activity relationship studies, *Bioorg. Chem.*, 2021, **115**, 105230, DOI: **10.1016/j.bioorg.2021.105230**.
- 54 E. Tampakakis and A. I. Mahmoud, The role of hormones and neurons in cardiomyocyte maturation, *Semin. Cell Dev. Biol.*, 2021, 118, 136–143, DOI: 10.1016/ j.semcdb.2021.03.026.
- 55 S. J. Sills and M. A. Rogawski, Mechanisms of action of currently used antiseizure drugs, *Neuropharmacology*, 2020, 168, 107966, DOI: 10.1016/j.neuropharm.2020.107966.
- 56 N. Ohashi and T. Kohno, Analgesic effect of acetaminophen: a review of known and novel mechanisms of action, *Front. Pharmacol.*, 2020, **11**, 580289, DOI: **10.3389/fphar.2020.580289**.
- 57 A. Jafarzadeh, M. Nemati, H. Khorramdelazad and Z. M. Hassan, Immunomodulatory properties of cimetidine: Its therapeutic potentials for treatment of immune-related diseases, *Int. Immunopharmacol.*, 2019, 70, 156–166, DOI: 10.1016/j.intimp.2019.02.026.
- 58 S. Zhao, R. Zhang, Y. Gao, Y. Cheng, S. Zhao, M. Li, H. Li and J. Dong, Immunosensor for Rapid and Sensitive Detection of Digoxin, *ACS Omega*, 2023, **8**, 15341–15349, DOI: **10.1021/acsomega.3c00571**.
- 59 H. Li, M. Zhang, L. Xiong, W. Feng and R. O. Williams III, Bioavailability improvement of carbamazepine via oral administration of modified-release amorphous solid dispersions in rats, *Pharmaceutics*, 2020, **12**, 1023, DOI: **10.3390/pharmaceutics12111023**.
- 60 J. Lee, X. Kong, B. Haymart, E. Kline-Rogers, S. Kaatz,V. Shah, M. A. Ali, J. Kozlowski, J. Froehlich andG. D. Barnes, Outcomes in patients undergoing

periprocedural interruption of warfarin or direct oral anticoagulants, *J. Thromb. Haemostasis*, 2022, **20**, 2571–2578, DOI: **10.1111/jth.15850**.

- 61 Z. Cai, Y. Lin and J. Liang, Efficacy of salbutamol in the treatment of infants with bronchiolitis: A meta-analysis of 13 studies, *Medicine*, 2020, 99, e18657, DOI: 10.1097/MD.00000000018657.
- 62 N. M. Ibrahim, S. H. Fahim, M. Hassan, A. E. Farag and H. H. Georgey, Design and synthesis of ciprofloxacinsulfonamide hybrids to manipulate ciprofloxacin pharmacological qualities: Potency and side effects, *Eur. J. Med. Chem.*, 2022, **228**, 114021, DOI: **10.1016**/ **j.ejmech.2021.114021**.
- 63 A. Olasunkanmi and A. Isreal, A narrative review of codeine and preventive measures in mitigating against the widespread of its abuse and misuse, *J. Alcohol Drug Depend.*, 2019, 7, 323, DOI: **10.4172/2329-6488.1000323**.
- 64 H. J. Wang, E. C. H. Tan, T. Y. Chiang, W. C. Chen, C. C. Shen and Y. F. Ueng, Effect of repeated Shengmai-San administration on nifedipine pharmacokinetics and the risk/benefit under co-treatment, *J. Food Drug Anal.*, 2022, **30**, 111–127, DOI: **10.38212/2224-6614.3401**.
- 65 S. Tavakoli-Dastjerdi, M. Motavasselian, S. A. Emami, M. Mansourian, A. Sahebkar and A. Teimouri, Efficacy of a combination of herbal gel versus topical diltiazem (2%) in chronic anal fissure healing: a randomized doubleblind clinical trial, *J. HerbMed Pharmacol.*, 2019, 8, 139–145, DOI: 10.15171/jhp.2019.22.
- 66 M. Fiorillo, F. Tóth, F. Sotgia and M. P. Lisanti, Doxycycline, Azithromycin and Vitamin C (DAV): A potent combination therapy for targeting mitochondria and eradicating cancer stem cells (CSCs), *Aging (Albany NY)*, 2019, **11**, 2202–2216, DOI: **10.18632/aging.101905**.
- 67 J. L. Tarry-Adkins, I. D. Grant, S. E. Ozanne, R. M. Reynolds and C. E. Aiken, Efficacy and side effect profile of different formulations of metformin: a systematic review and metaanalysis, *Diabetes Ther.*, 2021, **12**, 1901–1914, DOI: **10.1007/s13300-021-01058-2**.
- 68 N. A. Khan, S. U. Khan, S. Ahmed, I. H. Farooqi, M. Yousefi, A. A. Mohammadi and F. Changani, Recent Trends in Disposal and Treatment Technologies of Emerging-Pollutants-A Critical Review, *Trends Anal. Chem.*, 2020, 122, 115744, DOI: 10.1016/j.trac.2019.115744.
- 69 Z. Dang, M. Arena and A. Kienzler, Fish toxicity testing for identification of thyroid disrupting chemicals, *Environ. Pollut.*, 2021, 284, 117374, DOI: 10.1016/j.envpol.2021.117374.
- 70 B. Huerta, S. Rodriguez-Mozaz, J. Lazorchak, D. Barcelo, A. Batt, J. Wathen and L. Stahl, Presence of pharmaceuticals in fish collected from urban rivers in the U.S. EPA 2008–2009 National Rivers and Streams Assessment, *Sci. Total Environ.*, 2018, **634**, 542–549, DOI: 10.1016/j.scitotenv.2018.03.387.
- 71 D. Reynolds, M. Huesemann, S. Edmundson, A. Sims,B. Hurst, S. Cady, N. Beirne, J. Freeman, A. Berger andS. Gao, Viral inhibitors derived from macroalgae,microalgae, and cyanobacteria: A review of antiviral

potential throughout pathogenesis, *Algal Res.*, 2021, 57, 102331, DOI: 10.1016/j.algal.2021.102331.

- 72 M. D. Machado and E. V. Soares, Impact of erythromycin on a non-target organism: Cellular effects on the freshwater microalga *Pseudokirchneriella subcapitata*, *Aquat. Toxicol.*, 2019, 208, 179–186, DOI: 10.1016/j.aquatox.2019.01.014.
- 73 J. Katz, A. Y. Kargi and R. Ramasamy, Re: Ibuprofen Alters Human Testicular Physiology To Produce a State of Compensated Hypogonadism, *Eur. Urol.*, 2018, **74**, 394– 395, DOI: **10.1016/j.eururo.2018.03.039**.
- 74 S. Yadav, S. Kumar and A. K. Haritash, A comprehensive review of chlorophenols: Fate, toxicology and its treatment, *J. Environ. Manage.*, 2023, 342, 118254, DOI: 10.1016/j.jenvman.2023.118254.
- 75 P. Sharma, P. Kaur, P. Ghanghas, J. Kaur and N. Kaushal, Selenium Ameliorates Ibuprofen Induced Testicular Toxicity by Redox Regulation, *Reprod. Toxicol.*, 2020, 96, 349–358, DOI: 10.1016/j.reprotox.2020.08.005.
- 76 S. Pang, Z. Lin, W.-J. Chen, S.-F. Chen, Y. Huang, Q. Lei, P. Bhatt, S. Mishra, S. Chen and H. Wang, High-efficiency degradation of methomyl by the novel bacterial consortium MF0904: Performance, structural analysis, metabolic pathways, and environmental bioremediation, *J. Hazard. Mater.*, 2023, 452, 131287, DOI: 10.1016/ j.jhazmat.2023.131287.
- 77 E. Felis, J. Kalka, A. Sochacki, K. Kowalska, S. Bajkacz,
 M. Harnisz and E. Korzeniewska, Antimicrobial pharmaceuticals in the aquatic environment occurrence and environmental implications, *Eur. J. Pharmacol.*, 2019, 866, 172813, DOI: 10.1016/j.ejphar.2019.172813.
- 78 A. S. Adeleye, J. Xue, Y. Zhao, A. A. Taylor, J. E. Zenobio, Y. Sun, Z. Han, O. A. Salawu and Y. Zhu, Abundance, fate, and effects of pharmaceuticals and personal care products in aquatic environments, *J. Hazard. Mater.*, 2022, 424, 127284, DOI: 10.1016/j.jhazmat.2021.127284.
- 79 D. Khurana, R. Pulicharla and S. K. Brar, Antibiotic-metal complexes in wastewaters: fate and treatment trajectory, *Environ. Int.*, 2021, **157**, 106863, DOI: **10.1016**/ j.envint.2021.106863.
- 80 L. Duan, Y. Zhang, B. Wang, Y. Zhou, F. Wang, Q. Sui, D. Xu and G. Yu, Seasonal occurrence and source analysis of pharmaceutically active compounds (PhACs) in aquatic environment in a small and medium-sized city, China, *Sci. Total Environ.*, 2021, **769**, 144272, DOI: **10.1016**/ j.scitotenv.2020.144272.
- 81 Y. Kuang, X. Guo, J. Hu, S. Li, R. Zhang, Q. Gao, X. Yang, Q. Chen and W. Sun, Occurrence and risks of antibiotics in an urban river in northeastern Tibetan Plateau, *Sci. Rep.*, 2020, 10, 20054, DOI: 10.1038/s41598-020-77152-5.
- 82 J. P. Bavumiragira, J. Ge and H. Yin, Fate and transport of pharmaceuticals in water systems: A processes review, *Sci. Total Environ.*, 2022, 823, 153635, DOI: 10.1016/j.scitotenv.2022.153635.
- 83 I. Eheneden, R. Wang and J. Zhao, Antibiotic removal by microalgae-bacteria consortium: Metabolic pathways and microbial responses, *Sci. Total Environ.*, 2023, 891, 164489, DOI: 10.1016/j.scitotenv.2023.164489.

- 84 Y. Chen, W.-J. Chen, Y. Huang, J. Li, J. Zhong, W. Zhang, Y. Zou, S. Mishra, P. Bhatt and S. Chen, Insights into the microbial degradation and resistance mechanisms of glyphosate, *Environ. Res.*, 2022, 215, 114153, DOI: 10.1016/ j.envres.2022.114153.
- 85 S. Bose, P. Senthil Kumar, D. V.-N. Vo, N. Rajamohan and R. Saravanan, Microbial degradation of recalcitrant pesticides: a review, *Environ. Chem. Lett.*, 2021, **19**, 3209– 3228, DOI: **10.1007/s10311-021-01236-5**.
- 86 N. Haleyur, E. Shahsavari, S. S. Jain, E. Koshlaf, V. B. Ravindran, P. D. Morrison, A. M. Osborn and A. S. Ball, Influence of bioaugmentation and biostimulation on PAH degradation in aged contaminated soils: Response and dynamics of the bacterial community, *J. Environ. Manage.*, 2019, 238, 49–58, DOI: 10.1016/j.jenvman.2019.02.115.
- 87 D. H. Liang, Y. Hu, J. Cheng and Y. Chen, Simultaneous sulfamethoxazole biodegradation and nitrogen conversion in low C/N ratio pharmaceutical wastewater by *Achromobacter* sp. JL9, *Sci. Total Environ.*, 2019, **703**, 135586, DOI: **10.1016/j.scitotenv.2019.135586**.
- 88 M. Narayanan, S. S. Ali and M. El-Sheekh, A comprehensive review on the potential of microbial enzymes in multipollutant bioremediation: Mechanisms, challenges, and future prospects, *J. Environ. Manage.*, 2023, 334, 117532, DOI: 10.1016/j.jenvman.2023.117532.
- 89 I. S. Moreira, V. S. Bessa, S. Murgolo, C. Piccirillo, G. Mascolo and P. M. L. Castro, Biodegradation of Diclofenac by the bacterial strain *Labrys portucalensis* F11, *Ecotoxicol. Environ. Saf.*, 2018, **152**, 104–113, DOI: **10.1016**/ **j.ecoenv.2018.01.040**.
- 90 I. Liakh, D. Harshkova, P. Hrouzek, K. Bisova, A. Aksmann and B. Wielgomas, Green alga *Chlamydomonas reinhardtii* can effectively remove diclofenac from the water environment – A new perspective on biotransformation, *J. Hazard. Mater.*, 2023, **455**, 131570, DOI: **10.1016**/ j.jhazmat.2023.131570.
- 91 D. R. Olicon-Hernandez, M. Ortuzar, C. Pozo, J. González-López and E. Aranda, Metabolic capability of *Penicillium* oxalicum to transform high concentrations of antiinflammatory and analgesic drugs, *Appl. Sci.*, 2020, 10, 2479, DOI: 10.3390/app10072479.
- 92 C. V. Ungureanu, L. Favier and G. E. Bahrim, Improving Biodegradation of Clofibric Acid by *Trametes pubescens* through the Design of Experimental Tools, *Microorganisms*, 2020, 8, 1243, DOI: 10.3390/ microorganisms8081243.
- 93 P. Bhatt, E. R. Rene, Y. Huang, X. Wu, Z. Zhou, J. Li, A. J. Kumar, A. Sharma and S. Chen, Indigenous bacterial consortium-mediated cypermethrin degradation in the presence of organic amendments and Zea mays plants, *Environ. Res.*, 2022, 212, 113137, DOI: 10.1016/ j.envres.2022.113137.
- 94 W. Zhang, W. J. Chen, S.-F. Chen, Q. Lei, J. Li, P. Bhatt, S. Mishra and S. Chen, Cellular Response and Molecular Mechanism of Glyphosate Degradation by *Chryseobacterium* sp. Y16C, *J. Agric. Food Chem.*, 2023, 71, 6650–6661, DOI: 10.1021/acs.jafc.2c07301.

- 95 T. Hua, S. Li, F. Li, B. S. Ondon, Y. Liu and H. Wang, Degradation performance and microbial community analysis of microbial electrolysis cells for erythromycin wastewater treatment, *Biochem. Eng. J.*, 2019, **146**, 1–9, DOI: **10.1016/j.bej.2019.02.008**.
- 96 Z. Dong, X. Yan, J. Wang, L. Zhu, J. Wang, C. Li, W. Zhang, S. Wen and Y. M. Kim, Mechanism for biodegradation of sulfamethazine by *Bacillus cereus* H38, *Sci. Total Environ.*, 2022, 809, 152237, DOI: 10.1016/j.scitotenv.2021.152237.
- 97 F. Yang, H. Jian, C. Wang, Y. Wang, E. Li and H. Sun, Effects of biochar on biodegradation of sulfamethoxazole and chloramphenicol by *Pseudomonas stutzeri* and *Shewanella putrefaciens*: Microbial growth, fatty acids, and the expression quantity of genes, *J. Hazard. Mater.*, 2021, **406**, 124311, DOI: **10.1016/j.jhazmat.2020.124311**.
- 98 J. Ren, Z. Wang, L. Deng, D. Niu, B. Fan, T. Huhe, Z. Li, J. Zhang and C. Li, Biodegradation of erythromycin by *Delftia lacustris* RJJ-61 and characterization of its erythromycin esterase, *J. Basic Microbiol.*, 2021, **61**, 55–62, DOI: **10.1002/jobm.202000613**.
- 99 J. Yang, Z. Q. Zhao, M. Wang, K. F. Yu, T. Zhang, H. Lin and H. B. Zheng, Biodegradation of tylosin in swine wastewater by *Providencia stuartii* TYL-Y13: Performance, pathway, genetic background, and risk assessment, *J. Hazard. Mater.*, 2022, 440, 129716, DOI: 10.1016/j.jhazmat.2022.129716.
- 100 J. Zhang, X. Li, H. Lei, R. Zhao, W. Gan, K. Zhou and B. Li, New insights into thiamphenicol biodegradation mechanism by *Sphingomonas sp.* CL5. 1 deciphered through metabolic and proteomic analysis, *J. Hazard. Mater.*, 2022, 426, 128101, DOI: 10.1016/j.jhazmat.2021.128101.
- 101 X. X. Kong, J. L. Jiang, B. Qiao, H. Liu, J. S. Cheng and Y. J. Yuan, The biodegradation of cefuroxime, cefotaxime and cefpirome by the synthetic consortium with probiotic *Bacillus clausii* and investigation of their potential biodegradation pathways, *Sci. Total Environ.*, 2019, 651, 271–280, DOI: 10.1016/j.scitotenv.2018.09.187.
- 102 S. Shao, Y. Hu, J. Cheng and Y. Chen, Biodegradation mechanism of tetracycline (TEC) by strain *Klebsiella* sp. SQY5 as revealed through products analysis and genomics, *Ecotoxicol. Environ. Saf.*, 2019, **185**, 109676, DOI: **10.1016/j.ecoenv.2019.109676**.
- 103 E. Rivera-Gutierrez, J. J. Ramírez-García, S. H. Pavón Romero, M. M. Rodríguez, A. Ramírez-Serrano and A. Jiménez-Marin, Dicloxacillin degradation with freeliving bacteria, *Water, Air, Soil Pollut.*, 2020, 231, 1–13, DOI: 10.1007/s11270-020-4456-7.
- 104 N. Kamal, A. Tarafdar, A. Sinha and V. Kumar, Effect of Glucose Cometabolism on Biodegradation of Gabapentin (an Anticonvulsant Drug) by Gram-Positive Bacteria *Micrococcus luteus* N. ISM. 1, *Appl. Biochem. Microbiol.*, 2020, 56, 433–440, DOI: 10.1134/S0003683820040067.
- 105 S. Sharma, H. Setia and A. P. Toor, Assessing the bioremediation potential of indigenously isolated *Klebsiella sp.* WAH1 for diclofenac sodium: optimization, toxicity and metabolic pathway studies, *World J. Microbiol. Biotechnol.*, 2021, 37, 1–12, DOI: 10.1007/s11274-021-02998-4.

- 106 M. Dabrowska, B. Muszyńska, M. Starek, P. Żmudzki and W. Opoka, Degradation pathway of cephalosporin antibiotics by in vitro cultures of *Lentinula edodes* and *Imleria badia*, *Int. Biodeterior. Biodegrad.*, 2018, **127**, 104– 112, DOI: **10.1016/j.ibiod.2017.11.014**.
- 107 L. S. Copete-Pertuz, J. Plácido, E. A. Serna-Galvis, R. A. Torres-Palma and A. Mora, Elimination of isoxazolylpenicillins antibiotics in waters by the ligninolytic native colombian strain *Leptosphaerulina* sp. considerations on biodegradation process and antimicrobial activity removal, *Sci. Total Environ.*, 2018, **630**, 1195–1204, DOI: **10.1016/j.scitotenv.2018.02.244**.
- 108 B. Muszynska, P. Żmudzki, J. Lazur, K. Kała, K. Sułkowska-Ziaja and W. Opoka, Analysis of the biodegradation of synthetic testosterone and 17α-ethynylestradiol using the edible mushroom *Lentinula edodes*, 3 *Biotech*, 2018, 8, 1– 15, DOI: 10.1007/s13205-018-1458-x.
- 109 J. de Jesus Menk, A. I. S. do Nascimento, F. G. Leite, R. A. de Oliveira, A. F. Jozala, J. M. de Oliveira Junior, M. V. Chaud and D. Grotto, Biosorption of pharmaceutical products by mushroom stem waste, *Chemosphere*, 2019, 237, 124515, DOI: 10.1016/j.chemosphere.2019.124515.
- 110 D. R. Olicon-Hernandez, M. Ortuzar, C. Pozo, J. González-López and E. Aranda, Metabolic capability of *Penicillium* oxalicum to transform high concentrations of antiinflammatory and analgesic drugs, *Appl. Sci.*, 2020, 10, 2479, DOI: 10.3390/app10072479.
- 111 R. Ahumada-Rudolph, V. Novoa, J. Becerra, C. Cespedes and J. R. Cabrera-Pardo, Mycoremediation of oxytetracycline by marine fungi mycelium isolated from salmon farming areas in the south of Chile, *Food Chem. Toxicol.*, 2021, **152**, 112198, DOI: **10.1016/j.fct.2021.112198**.
- 112 J. Ren, Z. Wang, L. Deng, D. Niu, Huhetaoli, Z. Li, L. Dong, J. Zhang, R. Zhang and C. Li, Degradation of erythromycin by a novel fungus, Penicillium oxalicum RJJ-2, and the degradation pathway, *Waste Biomass Valorization*, 2021, 12, 4513–4523, DOI: 10.1007/s12649-021-01343-y.
- 113 A. Chatterjee and J. Abraham, Mycoremediation of 17 β-Estradiol Using *Trichoderma citrinoviride* Strain AJAC3 along with Enzyme Studies, *Environ. Prog. Sustainable Energy*, 2019, **38**, 13142, DOI: **10.1002/ep.13142**.
- 114 R. Manasfi, S. Chiron, N. Montemurro, S. Perez and M. Brienza, Biodegradation of fluoroquinolone antibiotics and the climbazole fungicide by Trichoderma species, *Environ. Sci. Pollut. Res.*, 2020, 27, 23331–23341, DOI: 10.1007/s11356-020-08442-8.
- 115 T. Zhang, L. Cai, B. Xu, X. Li, W. Qiu, C. Fu and C. Zheng, Sulfadiazine biodegradation by *Phanerochaete chrysosporium*: Mechanism and degradation product identification, *Chemosphere*, 2019, 237, 124418, DOI: 10.1016/j.chemosphere.2019.124418.
- 116 A. Stenholm, M. Hedeland, T. Arvidsson and C. E. Pettersson, Removal of diclofenac from a non-sterile aqueous system using *Trametes versicolor* with an emphasis on adsorption and biodegradation mechanisms, *Environ. Technol.*, 2019, **40**, 2460–2472, DOI: **10.1080/09593330.2018.1444098**.

- 117 C. Song, Y. Wei, Y. Qiu, Y. Qi, Y. Li and Y. Kitamura, Biodegradability and mechanism of florfenicol via *Chlorella* sp. UTEX1602 and L38: experimental study, *Bioresour. Technol.*, 2019, 272, 529–534, DOI: 10.1016/ j.biortech.2018.10.080.
- 118 C. Song, Y. Wei, J. Sun, Y. Song, S. Li and Y. Kitamura, Biodegradation and metabolic fate of thiamphenicol via Chlorella sp. UTEX1602 and L38, *Bioresour. Technol.*, 2020, 296, 122320, DOI: 10.1016/j.biortech.2019.122320.
- 119 L. Jalowiecki, G. Płaza, H. Ejhed and M. Nawrotek, Aerobic biodegradation of norfloxacin and ofloxacin by a microbial consortium, *Arch. Environ. Prot.*, 2019, 45, 40–47, DOI: 10.24425/aep.2019.130240.
- 120 S. Shao and X. Wu, Microbial degradation of tetracycline in the aquatic environment: a review, *Crit. Rev. Biotechnol.*, 2020, **40**, 1010–1018, DOI: **10.1080/07388551.2020.1805585**.
- 121 S. N. Malik, P. C. Ghosh, A. N. Vaidya and S. N. Mudliar, Hybrid ozonation process for industrial wastewater treatment: Principles and applications: A review, *J. Water Process Eng.*, 2020, 35, 101193, DOI: 10.1016/j.jwpe.2020.101193.
- 122 A. Marchlewicz, U. Guzik, W. Smulek and D. Wojcieszynska, Exploring the Degradation of Ibuprofen by Bacillus thuringiensis B1(2015b): The New Pathway and Factors Affecting Degradation, *Molecules*, 2017, 22, 1676, DOI: 10.3390/molecules22101676.
- 123 J. Wang and S. Wang, Microbial degradation of sulfamethoxazole in the environment, *Appl. Microbiol. Biotechnol.*, 2018, 102, 3573–3582, DOI: 10.1007/s00253-018-8845-4.
- 124 A. S. Al Hosni, J. K. Pittman and G. D. Robson, Microbial degradation of four biodegradable polymers in soil and compost demonstrating polycaprolactone as an ideal compostable plastic, *Waste Manage.*, 2019, **97**, 105–114, DOI: **10.1016/j.wasman.2019.07.042**.
- 125 L. Yu, Y. Wang, X. Shan, F. Ma and H. Guo, Harnessing Paenarthrobacter ureafaciens YL1 and Pseudomonas koreensis YL2 Interactions to Improve Degradation of Sulfamethoxazole, *Microorganisms*, 2022, **10**, 648, DOI: **10.3390/microorganisms10030648**.
- 126 J. P. Fernandes, C. M. R. Almeida, M. A. Salgado, M. F. Carvalho and A. P. Mucha, Pharmaceutical Compounds in Aquatic Environments—Occurrence, Fate and Bioremediation Prospective, *Toxics*, 2021, 9, 257, DOI: 10.3390/toxics9100257.
- 127 T. Velempini, E. Prabakaran and K. Pillay, Recent developments in the use of metal oxides for photocatalytic degradation of pharmaceutical pollutants in water—a review, *Mater. Today Chem.*, 2021, **19**, 100380, DOI: **10.1016/j.mtchem.2020.100380**.
- 128 Y. Xue, P. Du, A. A. I. Shendi and B. Yu, Mercury bioremediation in aquatic environment by genetically modified bacteria with self-controlled biosecurity circuit, *J. Cleaner Prod.*, 2022, 337, 130524, DOI: 10.1016/ j.jclepro.2022.130524.
- 129 I. Hussain, G. Aleti, R. Naidu, M. Puschenreiter, Q. Mahmood, M. M. Rahman, F. Wang, S. Shaheen, J. H. Syed and T. G. Reichenauer, Microbe and plant

assisted-remediation of organic xenobiotics and its enhancement by genetically modified organisms and recombinant technology: A review, *Sci. Total Environ.*, 2018, **628**, 1582–1599, DOI: **10.1016/j.scitotenv.2018.02.037**.

- 130 R. Kent and N. Dixon, Contemporary Tools for Regulating Gene Expression in Bacteria, *Trends Biotechnol.*, 2020, 38, 316–333, DOI: 10.1016/j.tibtech.2019.09.007.
- 131 P. Sharma, A. Bano, S. P. Singh, S. Sharma, C. Xia, A. K. Nadda, S. S. Lam and Y. W. Tong, Engineered microbes as effective tools for the remediation of polyaromatic aromatic hydrocarbons and heavy metals, *Chemosphere*, 2022, **306**, 135538, DOI: **10.1016**/ **j.chemosphere.2022.135538**.
- 132 M. F. Adegboye, O. B. Ojuederie, P. M. Talia and O. O. Babalola, Bioprospecting of microbial strains for biofuel production: metabolic engineering, applications, and challenges, *Biotechnol. Biofuels*, 2021, 14, 5, DOI: 10.1186/s13068-020-01853-2.
- 133 P. Bhatt, K. Bhatt, A. Sharma, W. Zhang, S. Mishra and S. Chen, Biotechnological basis of microbial consortia for the removal of pesticides from the environment, *Crit. Rev. Biotechnol.*, 2021, 41, 317–338, DOI: 10.1080/ 07388551.2020.1853032.
- 134 P. Sharma, P. Kaur, P. Ghanghas, J. Kaur and N. Kaushal, Selenium Ameliorates Ibuprofen Induced Testicular Toxicity by Redox Regulation, *Reprod. Toxicol.*, 2020, 96, 349–358, DOI: 10.1016/j.reprotox.2020.08.005.
- 135 M. Aulestia, A. Flores, S. Acosta-Jurado, E. Santero and E. M. Camacho, Genetic Characterization of the Ibuprofen-Degradative Pathway of Rhizorhabdus wittichii MPO218, *Appl. Environ. Microbiol.*, 2022, 8, e0038822, DOI: 10.1128/aem.00388-22.
- 136 A. B. Patel, S. Shaikh, K. R. Jain, C. Desai and D. Madamwar, Polycyclic aromatic hydrocarbons: sources, toxicity, and remediation approaches, *Front. Microbiol.*, 2020, **11**, 562813, DOI: **10.3389/fmicb.2020.562813**.
- 137 K. T. Sriwong and T. Matsuda, Recent Advances in Enzyme Immobilization Utilizing Nanotechnology for Biocatalysis, *Org. Process Res. Dev.*, 2022, 26, 1857–1877, DOI: 10.1021/ acs.oprd.1c00404.
- 138 M. U. Saeed, N. Hussain, A. Sumrin, A. Shahbaz, S. Noor, M. Bilal, L. Aleya and H. M. N. Iqbal, Microbial bioremediation strategies with wastewater treatment potentialities – A review, *Sci. Total Environ.*, 2022, **818**, 151754, DOI: **10.1016/j.scitotenv.2021.151754**.
- 139 D. Pandey, A. Daverey and K. Arunachalam, Biochar: Production, Properties and Emerging role as a Support for Enzyme Immobilization, *J. Cleaner Prod.*, 2020, **255**, 120267, DOI: **10.1016/j.jclepro.2020.120267**.
- 140 A. R. Ismail and K. H. Baek, Lipase immobilization with support materials, preparation techniques, and applications: Present and future aspects, *Int. J. Biol. Macromol.*, 2020, 163, 1624–1639, DOI: 10.1016/j.ijbiomac.2020.09.021.
- 141 M. Masjoudi, M. Golgoli, Z. G. Nejad, S. Sadeghzadeh and S. M. Borghei, Pharmaceuticals Removal by Immobilized Laccase on Polyvinylidene Fluoride Nanocomposite with

Multi-Walled Carbon Nanotubes, *Chemosphere*, 2020, **263**, 128043, DOI: **10.1016/j.chemosphere.2020.128043**.

- 142 L. Wang, S. Guan, J. Bai, J. Gao, Y. Song, X. Zheng and Y. Jiang, Enzyme immobilized in BioMOFs: Facile synthesis and improved catalytic performance, *Int. J. Biol. Macromol.*, 2020, 144, 19–28, DOI: 10.1016/j.ijbiomac.2019.12.054.
- 143 P. R. Yaashikaa, M. Keerthana Devi and P. Senthil Kumar, Advances in the application of immobilized enzyme for the remediation of hazardous pollutant: A review, *Chemosphere*, 2022, 299, 134390, DOI: 10.1016/ j.chemosphere.2022.134390.
- 144 M. Primozic, G. Kravanja, Z. Knez, A. Crnjac and M. Leitgeb, Immobilized laccase in the form of (magnetic) cross-linked enzyme aggregates for sustainable diclofenac (bio)degradation, *J. Cleaner Prod.*, 2020, 275, 124121, DOI: 10.1016/j.jclepro.2020.124121.
- 145 J. Zur, A. Piński, J. Michalska, K. Hupert-Kocurek, A. Nowak, D. Wojcieszyńska and U. Guzik, A whole-cell immobilization system on bacterial cellulose for the paracetamol-degrading *Pseudomonas moorei* KB4 strain, *Int. Biodeterior. Biodegrad.*, 2020, **149**, 104919, DOI: **10.1016/j.ibiod.2020.104919**.
- 146 X. Wu, W. J. Chen, Z. Lin, Y. Huang, T. N.-M. E. Sebai, N. Alansary, D. E. El-Hefny, S. Mishra, P. Bhatt, H. Lu and S. Chen, Rapid Biodegradation of the Organophosphorus Insecticide Acephate by a Novel Strain *Burkholderia* sp. A11 and Its Impact on the Structure of the Indigenous Microbial Community, *J. Agric. Food Chem.*, 2023, 71, 5261–5274, DOI: 10.1021/acs.jafc.2c07861.
- 147 N. Kamal, R. Sindhu and P. C. Bhargava, Biodegradation of emerging organic pollutant gemfibrozil: Mechanism, kinetics and pathway modelling, *Bioresour. Technol.*, 2023, 374, 128749, DOI: 10.1016/j.biortech.2023.128749.
- 148 Y. Huang, W.-J. Chen, J. Li, M. A. Ghorab, N. Alansary, D. E. El-Hefny, G. S. El-Sayyad, S. Mishra, X. Zhang, P. Bhatt and S. Chen, Novel mechanism and degradation kinetics of allethrin using Bacillus megaterium strain HLJ7 in contaminated soil/water environments, *Environ. Res.*, 2022, 214, 113940, DOI: 10.1016/j.envres.2022.113940.
- 149 S. P. Sam, S. L. Ng and A. Rohana, Kinetics of biodegradation of phenol and p-nitrophenol by acclimated activated sludge, *J. Phys. Sci.*, 2018, **29**, 107–113, DOI: **10.21315/jps2018.29.s1.14**.
- 150 S. S. Patil and H. M. Jena, Process optimization and kinetic study of biodegradation of dimethyl phthalate by KS2, a novel strain of *Micrococcus* sp., *Sci. Rep.*, 2023, **13**, 3900, DOI: **10.1038/s41598-023-29256-x**.
- 151 G. Calero-Diaz, A. Monteoliva-García, J. C. Leyva-Díaz, C. López-López, J. Martín-Pascual, J. C. Torres and J. M. Poyatos, Impact of ciprofloxacin, carbamazepine and ibuprofen on a membrane bioreactor system: Kinetic study and biodegradation capacity, J. Chem. Technol. Biotechnol., 2017, 92, 2944–2951, DOI: 10.1002/jctb.5316.
- 152 L. Pan, J. Li, C. Li, X. Tang, G. Yu and Y. Wang, Study of ciprofloxacin biodegradation by a *Thermus* sp. isolated from pharmaceutical sludge, *J. Hazard. Mater.*, 2018, 343, 59–67, DOI: 10.1016/j.jhazmat.2017.09.009.